Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleMinireview—A Latin American Perspective On G Protein-Coupled Receptors

The Follitropin Receptor: Matching Structure and Function

Alfredo Ulloa-Aguirre and Teresa Zariñán
Molecular Pharmacology November 2016, 90 (5) 596-608; DOI: https://doi.org/10.1124/mol.116.104398
Alfredo Ulloa-Aguirre
Research Support Network, National University of Mexico and National Institutes of Health, Mexico City, Mexico
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Teresa Zariñán
Research Support Network, National University of Mexico and National Institutes of Health, Mexico City, Mexico
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

This article has a correction. Please see:

  • Corrections to “The Follitropin Receptor: Matching Structure and Function” - January 01, 2017

Visual Overview

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

Abstract

Follitropin, or follicle-stimulating hormone (FSH) receptor (FSHR), is a G protein-coupled receptor belonging to the glycoprotein hormone receptor family that plays an essential role in reproduction. Although its primary location is the gonad, the FSHR has also been reported in extragonadal tissues including bone, placenta, endometrium, liver, and blood vessels from a number of malignant tumors. The recently resolved crystal structure of FSH bound to the entire FSHR ectodomain has been instrumental in more clearly defining the role of this domain in ligand binding and receptor activation. Biochemical, biophysical, and structural data also indicate that the FSHR exists as a higher order structure and that it may heterodimerize with its closely related receptor, the luteinizing hormone receptor; this association may have physiologic implications during ovarian follicle maturation given that both receptors may simultaneously coexist in the same cell. FSHR heterodimerization is unique to the ovary because in the testes, gonadotropin receptors are expressed in separate compartments. FSHR self-association appears to be required for receptor coupling to multiple effectors and adaptors, for the activation of multiple signaling pathways and the transduction of asymmetric signaling, and for negative and positive receptor cooperativity. It also provides a mechanism through which the glycosylation variants of FSH may exert distinct and differential effects at the target cell level. Given its importance in regulating activation of distinct signaling pathways, functional selectivity at the FSHR is briefly discussed, as well as the potential implications of this particular functional feature on the design of new pharmacological therapies in reproduction.

Introduction

The pituitary gonadotropin hormones, luteinizing hormone (LH) and follicle-stimulating hormone (FSH), are synthesized in gonadotrope cells and play a key role in the control of gonadal function and reproduction (Huhtaniemi et al., 1982; Bousfield et al., 1996; Richards et al., 2002). Both gonadotropins, as well as placental chorionic gonadotropin (CG) and thyroid-stimulating hormone (TSH) produced by pituitary thyrotropes, belong to the family of glycoprotein hormones (GPH) (Pierce and Parsons, 1981; Ulloa-Aguirre and Timossi, 1998; Szkudlinski, 2015).

Their cognate receptors (FSHR, LHCGR, and TSHR) belong to the highly conserved subfamily of the G protein-coupled receptor (GPCR) superfamily, the so-called Rhodopsin family, and more specifically, to the δ-group of this large class of GPCRs (Simoni et al., 1997; Kleinau et al., 2013; Troppmann et al., 2013). GPH receptors (GPHR) are characterized by a large NH2-terminal extracellular domain, or ectodomain, where recognition and binding of their corresponding ligands occur. This extracellular domain contains a central structural motif of imperfect leucine-rich repeats (12 in the FSHR), a motif that is shared with a number of other membrane receptors involved in ligand selectivity and specific protein-protein interactions (Fig. 1A) (Bogerd, 2007). The carboxyl-terminal end of the large extracellular domain includes the so-called hinge region, which structurally links the leucine-rich extracellular domain with the serpentine, seven transmembrane domain (7 TMD) of GPHRs and leads to receptor activation and signaling functionality. In all GPHRs, the hinge region is involved in high affinity hormone binding, receptor activation, and the intramolecular signal transduction and/or silencing of basal receptor activity in the absence of a ligand (Mueller et al., 2010).

Fig. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.

Schematic representation of the human FSHR structure, including the amino acid sequence (circles). Numbering of amino acid residues includes the leader sequence. (A) Hormone binding subdomain (HBSD) of the extracellular domain. The FSHR residues that are buried in the FSH/FSHR interface and located in the high affinity binding site are shown in colored circles. Green shows the FSH α-subunit residues only; blue shows the FSH β-subunit residues only: orange denotes residues from both subunits that interact with the FSHR. Also shown are the locations of naturally occurring receptor mutations in this domain that affect function. The location of the mutation leading to promiscuous ligand binding is shown in magenta (Ser128), whereas the residues whose replacement provokes loss-of-function of the receptor are shown in red; the majority of mutations at these sites lead to trafficking-defective FSHR molecules (reviewed in Ulloa-Aguirre et al., 2014b). β-Strands located in the concave (corresponding to the leucine-rich repeats) or convex surface of the HBSD are indicated by the colorless arrows. Disulfide bonds are shown as broken lines and glycosylation by the arbor-like structure [schematic according to Fan and Hendrickson (2005) structure]. (B) Signal specificity subdomain and seven transmembrane domain (7 TMD) including the extracellular loops (EL), intracellular loops (IL), and carboxyl-terminal domain (Ctail). The regular secondary structure elements of the leucine-rich repeats 11 and 12 are shown as colorless arrows for the β-strands and as a cylinder for the α-helix. α-Helices of the 7 TMD (I to VII) are also shown as cylinders. The Y335 residue, which interacts with a binding pocket located in the interface of the FSH α-and β-subunits (represented by the brown and green freeform drawings, respectively) is surrounded by a broken-line oval. [Schematic according to the structure reported by Jiang et al. (2012).] The location of the naturally occurring loss-of-function mutations reported to date are shown as red-colored circles, whereas the location of gain-of-function mutations are shown in green. Mutations at Asp567, Iso545, and Thr449 lead to promiscuous activation of the receptor by other glycoprotein hormones, whereas the mutation at Asn431 leads to altered desensitization and internalization of the FSHR (Casas-Gonzalez et al., 2012). Mutation at Val514 (magenta circle in the extracellular loop 2) led to increased plasma membrane expression of the receptor and OHSS at low FSH doses (Desai et al., 2015). Also indicated are amino acid residues that are involved in APPL1 interaction (Lys393) with the intracellular loop 1, as well as the most common location of FSHR polymorphisms (N680 and A307) (yellow circles). Additionally, the schematics show the location of some important motifs and sequences involved in receptor function: a) The sequence involved in internal agonist activity (FNPCEDIMGY sequence, shaded in green); b) Motifs involved in receptor trafficking [F(X6)LL and BXXBB, the latter motif found reversed at the NH2-terminal end of the carboxy-terminal tail]; c) Motifs involved in G protein coupling and receptor activation (ERW and NPXXY motifs at the TMD III-intracellular loop 2 junction and within TMD VII, respectively; and another reversed BXXBB motif in intracellular loop 3); d) The Ser/Thr cluster for receptor phosphorylation by GRK 2 (class B cluster at the Ctail); and e) The target residues for palmitoylation (Cys 644, 646, and 672) (Ulloa-Aguirre et al., 2007a; 2014a,b; Desai et al., 2013; Bramble et al., 2016). Disulfide bonds are shown as broken lines.

The FSHR is primarily expressed by specific cells in the female and male gonads (Vassart et al., 2004). In the ovary, the FSHR is expressed in the granulosa cells where FSH-stimulated activation leads to growth and maturation of ovarian follicles and estrogen production. In the testes, the FSHR is expressed in the Sertoli cells of the seminiferous tubules where it supports their growth and maturation and, hence, indirectly promotes spermatogenesis (Dias et al., 2002).

This review summarizes the most important structural and functional aspects of the FSHR that may eventually impact the design and development of new pharmacological approaches in the treatment of reproductive disease.

FSHR Structure

In humans, the FSHR gene is located on chromosome 2p21-p16 (Gromoll et al., 1994). The coding region of this gene consists of 10 exons, ranging in size from 69 to 1234 bp, and 9 introns sized from 108 to 15 kb (Gromoll et al., 1996). The receptor protein is comprised by 695 amino acid residues; the first 17 amino acids encode the signal, or leader sequence, resulting in a mature, cell surface plasma membrane expressed FSHR of 678 amino acid residues with a molecular weight of 75 kDa as predicted from its cDNA (Dias et al., 2002). Nevertheless, N-glycosylation of three of four possible glycosylation sites can yield mature receptor forms with an approximate molecular weight of 80-87 kDa.

Several heterogeneous FSHR splice variants have been detected in various animals species (Gromoll et al., 1993; Khan et al., 1993; Rajapaksha et al., 1996; Yarney et al., 1997a; Tena-Sempere et al., 1999; Babu et al., 2001; Neubauer et al., 2006), including humans (Kelton et al., 1992; Song et al., 2002; Gerasimova et al., 2010; Robinson et al., 2010; Zhou et al., 2013; Karakaya et al., 2014). Because many of the detected alternative transcripts are not translated into a protein or translation yields severely misfolded proteins unable to traffic to the cell surface plasma membrane, the function and regulatory role of FSHR transcript variants has been scarcely studied. Two alternate splice transcripts of the ovine FSHR gene with an altered exon 10 deserve particular attention because of their potential functional consequences (Sairam et al., 1996, 1997; Yarney et al., 1997b; Babu et al., 1999, 2000). The first variant is similar to the full-length wild-type (WT) receptor except that differential splicing leads to divergence in the protein sequence at the carboxyl terminus and the variant is 25 amino acids shorter. This FSHR variant is expressed at the plasma membrane, fails to signal via the cAMP/PKA pathway, and behaves as a dominant negative receptor when coexpressed with the WT receptor in HEK293 cells (Sairam et al., 1996). The other variant is a FSHR consisting of a transcript encoding only exons 1–8, along with a non-FSHR single transmembrane domain, and a carboxyl-terminal extension characteristic of cytokine/growth factor receptors (Sairam et al., 1997). When expressed in granulosa cells, the growth promoting effects of this variant were independent of the cAMP/PKA pathway but were mediated by Ca2+ activation and ERK1/2-dependent pathways (Babu et al., 2000). Further studies demonstrated that this particular variant is also expressed in the mouse ovary and that it is upregulated by gonadotropin stimulation (Babu et al., 2001). More recent studies in ewes (Sullivan et al., 2013) found that the FSH-growth factor-like receptor was more highly expressed than the WT variant in follicles of all sizes, but particularly in medium size follicles obtained during early estrus, suggesting that this receptor isoform may play a role in follicle development in this particular animal species. Additional studies are still necessary to more precisely define the role of these and other FSHR transcript variants in the mediation of the pleiotropic effects of FSH (see below), particularly in humans.

Both the FSHR and its close relative, the LHCGR, exhibit a high degree of amino acid sequence homology. Although the extracellular domain amino acid sequences of the gonadotropin receptors are approximately 46% identical, the 7 TMD sequence portion of the receptors shares nearly 72% homology (Dias et al., 2002; Kleinau and Krause, 2009). Although this relatively high similarity between the 7 TMD of the gonadotropin receptors might suggest similar mechanisms of receptor activation, mutations in this domain leading to constitutive activation of the FSHR are extremely rare (Figs. 1B and 2) (see below), but this is not the case for the LHCGR (Ulloa-Aguirre et al., 2014a). This difference may be due to the relative stability of the FSHR 7 TMD in the inactive state compared with the LHCGR and the TSHR. In fact, constitutively active mutants of the latter receptors are more frequent and share the same location across the serpentine domain, indicating that those two receptors actually share common mechanisms of activation. In contrast, only two of the four FSHR constitutively active mutants identified to date share locations with the LHCGR and the TSHR constitutively active mutants (Ulloa-Aguirre et al., 2014a). Among the three domains of the gonadotropin receptors, the intracellular regions exhibit the lowest amino acid sequence homology (∼27% identity), with the exception of the NH2-ends of the carboxyl termini, which bear cysteine residues for palmitoylation and a primary sequence motif [Phe(x)6Leu-Leu] that regulates anterograde trafficking from the endoplasmic reticulum to the plasma membrane (Duvernay et al., 2004; Uribe et al., 2008). Both of these structural characteristics are common features of the rhodopsin-like GPCR subfamily.

Fig. 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 2.

Three-dimensional homology model of the FSH/FSHR complex is shown with mapped positions of the naturally occurring mutations at the FSHR. The 7 TMD constituted by transmembrane helices (H) 1–7 connected by intracellular (IL) and extracellular (EL) loops was modeled based on the determined active structure-conformation of the β2-adrenergic receptor (PMID: 21772288). The (monomeric) extracellular complex between the hinge region, the leucine-rich repeat domain (see Fig. 1A), and FSH were taken as suggested by a structure determined for a fragment (PMID: 22802634). The hinge region structurally links the leucine-rich repeat domain with the 7 TMD. The FSHR (backbone white-7 TMD, light beige-hinge/leucine-rich repeat domain) binds the hormone [FSHβ (brown) and FSHα (yellow), surface representation] at the extracellular side between the leucine-rich repeat domain and the hinge region. The exact orientation between the different components to each other is still unclear. The localization of naturally occurring mutations is indicated by highlighted side chains of wild-type positions (atom spheres without hydrogen). Gain-of-function mutations (green) are characterized by an increase in basal activity or by causing promiscuous ligand binding (magenta spheres or magenta boxes). Few substitutions at the 7 TMD lead to increased basal activity and, simultaneously, to promiscuous hormone sensitivity. Loss-of-function mutations are indicated in red. This spatial arrangement and mapping helps to match functional data with structural information, allowing extraction of important regions for maintenance of properties necessary for signal transduction, including the structural fold or obligate side-chain interactions. Ctail, carboxyl-terminal tail.

Extragonadal Expression of the FSHR

Although for many years the FSHR was thought to be localized exclusively in the gonads, recently it was reported that FSHR exists in extragonadal tissues where it has been purported to have distinct physiologic roles. Extragonadal sites where the FSHR has been localized include bone osteoclasts (Sun et al., 2006, 2010), monocytes (Robinson et al., 2010; Cannon et al., 2011), endothelial cells from the umbilical vein (Stilley et al., 2014b), tumor vasculature and metastases (Radu et al., 2010; Siraj et al., 2013; Planeix et al., 2015), different sites of the female reproductive tract, the developing placenta (Stilley et al., 2014a), and the liver (Song et al., 2016). Data on the expression (mRNA and protein) of either the FSHR WT or the splice variant originally identified in bovine granulosa cells (Rajapaksha et al., 1996) in osteoclasts and monocytes (Robinson et al., 2010) and, consequently, on the role of FSH in bone function are still quite controversial (Seibel et al., 2006; Sun et al., 2006, 2010; Gao et al., 2007; Prior, 2007; Williams, 2007; Allan et al., 2010; Cannon et al., 2011). Meanwhile, immunohistochemical studies using monospecific anti-FSHR antibodies have documented the expression of human FSHR in blood vessels from a number of malignant tumors (Radu et al., 2010; Planeix et al., 2015) and tumor metastases (Siraj et al., 2013). Although the authors posit that FSHR at these locations may contribute to the growth and expansion of tumor tissue by promoting angiogenesis, further studies are still necessary to validate these findings given that such claims can lead to concerns among women undergoing hormone therapy during in vitro fertilization or menopause, conditions where FSH levels may be extremely high. In a series of studies, Stilley et al. (2014a,b) recently identified FSHR in several nonovarian reproductive tissues. Interestingly, feto-placental haploinsufficiency of the Fshr in mice was associated with placental growth defects and fetal loss in both heterozygous and homozygous null Fshr animals (Stilley et al., 2014a). More recently, a role for the FSHR in liver tissue was proposed (Song et al., 2016), and in this report, the authors claimed that the FSHR may be involved in the expression of the low-density-lipoprotein receptor and in the regulation of low-density-lipoprotein cholesterol clearance. However, this study, which focused on menopausal women, did not account for the role of estrogens in this process. In conclusion, further studies are still warranted to elucidate more clearly the expression and physiologic significance of extragonadal FSHRs. It still needs to be determined whether they are structurally similar to those primarily expressed in the gonads or if they are splice variants of the WT receptor that when expressed in the plasma membrane in sufficient quantities may provoke a biologic effect upon exposure to physiologic concentrations of the agonist. Such studies will undoubtedly lead to assertions on the role of FSH in many extragonadal activities.

Ligand Binding and Receptor Activation: Role of the FSHR Ectodomain

The FSHR extracellular domain harbors both the binding site for FSH and the region necessary for ligand-induced receptor activation. Although previous biochemical and in silico studies (Jiang et al., 1995; Schmidt et al., 2001) had predicted the relationship between the GPHRs ectodomain and GPH agonist binding and recognition, it was not until the first structure of the FSH in complex with the extracellular-hormone binding domain of the FSHR (FSHRHB) was established (Fan and Hendrickson, 2005) that this relationship was fully documented. This model, however, did not include the hinge region, which, based on biochemical studies, had been considered a separate structure essential for FSHR activation (Costagliola et al., 2002; Bruysters et al., 2008; Agrawal and Dighe, 2009). As previously predicted, the Fan-Hendrickson structure showed that FSH binds to FSHRHB like a “handclasp,” (Jiang et al., 1995), that most β-strands in the inner surface participate in FSH binding, and that both hormone subunits (noncovalently linked α- and β-subunits, a hallmark of all GPHs) are involved in the specificity of binding to the receptor, with charge and stereochemical dominance dictating specificity. More importantly, the structure revealed that carbohydrates do not participate in the binding interface of the FSH–FSHRHB structure, but rather are sequestered in the periphery of the complex (Fan and Hendrickson, 2005, 2007).

Seven years later, the crystal structure of FSH bound to the entire FSHR ectodomain (FSHRED) was determined (Jiang et al., 2012, 2014a). The structure has more clearly elucidated the role of the FSHR (and other GPHRs as well) extracellular domain in ligand binding and, more importantly, in receptor activation. The FSHR extracellular domain structure identified the hinge region (or signal specificity subdomain) as an integral part of the ectodomain (Fig. 1B). As earlier biochemical studies on the FSHR and TSHR had indicated, this particular region was also confirmed to play an essential role in ligand- and/or mutation-provoked receptor activation (Zhang et al., 2000; Vlaeminck-Guillem et al., 2002; Chen et al., 2003; Vassart et al., 2004; Agrawal and Dighe, 2009). In fact, these and more recent studies (Bruser et al., 2016) strongly suggest that the ectodomain of the GPHRs acts as a tethered inverse agonist that switches to an agonist upon ligand binding (i.e., the unoccupied hinge region inhibits FSHR activation) and activation of an internal agonist unit located in the carboxyl-terminal end of the hinge region (Fig. 1B). The hinge region bears a sulfated Tyr residue (Y335) that interacts with a binding pocket located in the interface of the α- and β-subunits of FSH and formed via conformational changes of the ligand occurring after binding to the hormone-binding subdomain (HBSD) (Fig. 1B). The sulfated Y335 is located right after a rigid hairpin loop that lifts upon Y335 binding to the pocket unlocking the inhibitory effects of the loop on the 7TMD; this process leads to conformational changes in the latter domain and, eventually, to activation of the receptor. This tethered inverse agonist region in the extracellular domain had been previously mapped to the hairpin loop segments 296–331 of the receptor (Fig. 1B) (Agrawal and Dighe, 2009). As part of this process, a fixed short helix formed by residues S273 to A279 rotates and acts as a pivot, further contributing to the conformational change of the FSHR signal specificity subdomain . The importance of this helix movement in FSHR activation is underscored by the finding that the S273I FSHR mutant constitutively activates the receptor (Nakabayashi et al., 2000). In addition, the disulfide bond C275-C346 (Fig. 1B) fastens the last β-strand (leucine-rich repeat 12) to the short helix forming a rigid body. Additionally, the disulfide C276-C356 bridge ties this helix to the last few residues before the first TMD. Because of these constraints, the movement of the hairpin loop that occurs upon ligand binding could directly influence the conformation of the TMD helix 1, thereby promoting rearrangement within the remaining TMDs and ultimately leading to receptor activation. Given the similarity among the structures of GPHs and GPHRs, it is highly possible that all GPHRs share this two-step recognition process (ligand recruitment followed by signal specificity subdomain sulfated tyrosine docking—Y335 in the FSHR, Y331 in the LHCGR, and Y385 in the TSHR). In fact, FSH, LHCG, and TSH receptor mutants lacking this critical sulfated tyrosine residue lose their sensitivity to cognate ligands (Costagliola et al., 2002; Bonomi et al., 2006; Bruysters et al., 2008). Also, FSH mutants with substitutions in amino acid residues located below the sulfated tyrosine binding pocket (αF74E) or at the potential exosite (βL73E) exhibited increased signaling by pushing the hairpin loop up toward the top of the pocket (Jiang et al., 2012).

Biochemical, mutational, and in silico studies suggest that sites in the serpentine domain of the receptor, particularly the exoloops, which are extracellular projections of the TMDs, are also directly involved in receptor-ligand interaction and receptor activation. In fact, as supported by structural studies, exoloops 1 and 3, which are solvent exposed and accessible to gonadotropin hormone, may represent potential secondary gonadotropin binding sites, specifically at its α-subunit tips in the bound state (Fan and Hendrickson, 2005; Dupakuntla and Mahale, 2010). Moreover, according to mutagenic and functional studies, and the 7 TMD theoretical model (Jiang et al., 2014a), it seems that the exoloops interact with the hairpin loop of the hinge region to trigger FSHR activation; lifting of the sulfated Y335 to the FSHα/β binding pocket frees the hinge-tethered exoloops, releasing the inhibitory influence of the ectodomain on receptor activation (Jiang et al., 2014a). Accordingly, mutations in residues located at the FSHR exoloops 1 to 3, in addition to altering the receptor’s intracellular traffic [e.g., the N431I and L501F FSHR mutants (Casas-Gonzalez et al., 2012; Banerjee et al., 2015)], may also lead to attenuation of either agonist binding (Ji and Ji, 1995), FSH-stimulated signal transduction (Touraine et al., 1999; Sohn et al., 2002; Dupakuntla et al., 2012; Banerjee et al., 2015), or foster constitutive activation of the receptor (Casas-Gonzalez et al., 2012). The relationship between the FSHR exoloops and the hinge region is further supported by studies of the TSH receptor in which particular residues [e.g., Y563 and K565 at the exoloop 2 (Y511 and K513 in the FSHR)] are crucial for ligand-stimulated receptor activation (Kleinau et al., 2007).

Another interesting nuance is the FSHR (and TSHR) promiscuity for ligand specificity that the receptors exhibit upon particular structural modifications induced by mutations (Figs. 1 and 2) in the extracellular domain and the 7 TMD, a phenomenon with important consequences in the clinical realm. GPH-GPHR pairs have evolved so that a limited number of residues at the “seat-belt” domain of the ligand and the leucine-rich repeats of the receptor at the HBSD (Fig. 1A) take part in electrostatic interactions at the receptor-hormone interface to define binding and specificity. Because of the structural similarities among the GPHs and the GPHRs, it is conceivable that a given GPHR may be “cross-activated” by a ligand other than its cognate ligand, albeit with low binding affinity and without triggering detectable basal receptor activation. Therefore, it is not surprising that substitutions of key residues that directly or indirectly participate in the interaction of the receptor with its cognate ligand may dampen structurally related ligand discrimination and result in the interaction of the altered receptor with other than its own cognate GPH. For example, the S128Y mutation at the FSHR (Figs. 1B and 2) may lead to pregnancy-associated ovarian hyperstimulation syndrome (OHSS) [a potentially life-threatening condition (Kumar et al., 2011)] due to increased affinity and responsiveness of the mutated FSHR to CG, which circulates at very high levels during the first trimester of pregnancy (De Leener et al., 2008). In this particular mutation, the S→Y replacement allows the FSHR to form a hydrogen bond with the αR95 residue of CG, which leads to receptor activation.

A different scenario is observed in the case of mutations leading to constitutive activation of the FSHR and concomitant promiscuous binding of CG and/or TSH. Most mutations leading to constitutive activation of the FSHR are located in the 7 TMD, and considerably fewer naturally occurring activating mutations have been identified in the FSHR compared with the highly related LHCGR (Figs. 1B and 2) (Ulloa-Aguirre et al., 2014a); this difference suggests that the FSHR is generally more resistant than the LHCGR to mutation-induced constitutive activity (Zhang et al., 2007), albeit that activating FSHR mutations are generally difficult to detect in the clinical setting, particularly in otherwise healthy men, as they may not be associated to an evident phenotype (Casas-Gonzalez et al., 2012). In fact, when mutations leading to ligand-independent activation of LHCGR were introduced into the FSHR, the level of detected constitutive activity was consistently lower (Kudo et al., 1996; Zhang et al., 2007). Meanwhile, the same mutations exhibited stronger FSHR promiscuous activation by CG and TSH (Zhang et al., 2007). Strikingly, similar promiscuous activation has been detected in three of six reported naturally occurring constitutively active mutants of the FSHR [reviewed in (Ulloa-Aguirre et al., 2014a); Fig. 2], indicating a close link between constitutive activation of the FSHR and ligand promiscuity, a phenomenon not observed in the other GPHRs (Montanelli et al., 2004b; Vassart et al., 2004). These FSHR constitutively active mutants leading to spontaneous OHSS [D567N at the junction of TMD 6 and intracellular loop 3; T449A at TMD 3; and I545T at TMD 5) (Fig. 2)] are particularly interesting because the mutations provoke conformational changes in the receptor structure that, aside from triggering modest constitutive activity, “relax” the binding specificity of the receptor and allow the altered receptor to bind and become activated by high concentrations of CG (Smits et al., 2003; Vasseur et al., 2003; Montanelli et al., 2004a; De Leener et al., 2006) or TSH (Smits et al., 2003; Montanelli et al., 2004b; De Leener et al., 2006) without altering receptor affinity to GPH. As discussed above, in the unliganded state, the signal specificity subdomain of the FSHR ectodomain exerts an inhibitory influence on the transmembrane domain, keeping the receptor in relative quiescence; upon agonist binding or when mutations are introduced at Ser273 (at the hinge region) (Nakabayashi et al., 2000), the tethered extracellular loops of the TMDs are freed from this inhibitory influence, which allows the TMDs to attain an active conformation (Jiang et al., 2012). In this scenario, the OHSS pathogenesis associated with these constitutively active mutants has been explained by low affinity promiscuous interaction of CG or TSH with the ectodomain of a mutant FSHR in the setting of a partially “unlocked” FSHR 7 TMD and high agonist concentrations, which leads to excessive follicular recruitment (De Leener et al., 2006). The ability of the FSHR constitutively active mutant D567N to become activated by CG and TSH has also been confirmed in animal models (Allan et al., 2009). Thus, partial activation of the 7 TMD facilitates receptor activation by relaxing the inhibitory constraints present in this domain and by making the FSHR more prone to full activation by high concentrations of other gonadotropins that share an identical α-subunit with FSH, which also directly participates in receptor binding (see above) (Montanelli et al., 2004b). Undoubtedly, knowing the entire FSHR structure in both the inactive and active states will further clarify the molecular mechanisms mediating promiscuous binding and activation of the FSHR in the presence of gain-of-function mutations.

It appears that the relative resistance of the FSHR to ligand-independent activation (and, consequently, to ligand promiscuity) reflects an evolutionary strategy in primates to prevent FSHR activation and the development of disease (e.g., OHSS) resulting from very high levels of circulating CG or TSH during pregnancy or primary hypothyroidism, respectively (Vassart and Costagliola, 2011).

Finally, the last concept concerning agonist binding and receptor activation pertains to FSHR interaction with and response to FSH variants with differential glycosylation. All glycoprotein hormones exhibit up to four N-linked oligosaccharides, and in human FSH, these oligosaccharides contribute to nearly 30% of the glycoprotein’s mass and are located in both the common α-subunit (α52 and α78) and the hormone specific β-subunit (β7 and β24) (Bousfield et al., 2015). Glycans, critical for FSH function, play important roles in subunit assembly, intracellular trafficking, heterodimer secretion, circulatory half-life, receptor binding, and signal transduction at the target cell level (Ulloa-Aguirre et al., 2003). Furthermore, glycans in glycoprotein hormones are not homogeneous structures, but rather highly heterogeneous structures in terms of both oligosaccharide composition and glycan location within the protein core of the heterodimer (Ulloa-Aguirre et al., 2003; Bousfield et al., 2014b). Differential glycosylation of FSHβ appears to be closely related to physiologically distinct functions, because hypoglycosylated variants are more abundant in women of reproductive age, exhibit greater receptor-binding affinity, and occupy more FSH binding sites than fully glycosylated FSH, which predominates in men and in postmenopausal women (Butnev et al., 2015). Several studies have also indicated that the amount of glycans, the particular carbohydrate composition, and the structure of the attached oligosaccharides influence both binding and response to the FSH stimulus in vitro and in vivo (Creus et al., 2001; Barrios-De-Tomasi et al., 2002). An intriguing question is how FSH glycosylation influences FSHR binding and activation and leads to differential signal transduction, given that according to the 3-dimensional structure of the FSHR ectodomain, FSH glycans play no role in the binding interface of the FSH/FSHR complex, but rather appear to be sequestered in the periphery of the complex (Dias, 2005; Fan and Hendrickson, 2005; Jiang et al., 2012, 2014a). In this regard, the structures of FSH and the FSHR ectodomain in complex with FSH (Dias and Van Roey, 2001; Fox et al., 2001; Dias, 2005; Fan and Hendrickson, 2005) predict contact between the GlcNac1 residue at position Asn52 of FSHα [which is indispensable for signaling (Matzuk and Boime, 1989; Matzuk et al., 1989; Flack et al., 1994)] and Tyr58 in FSHβ. It is therefore possible that structural variations in the α52 glycan may influence the stability and/or conformation of the FSH ligand, thereby compromising the ability of the FSH/FSHR complex to affect signal transduction. Recently, extended molecular dynamics simulation studies on complexes of the FSHR HBSD (Fan and Hendrickson, 2005) and different FSH glycoforms were conducted (Meher et al., 2015). This study revealed that FSHR in complex with hypo(di-)glycosylated FSH exhibited greater conformational flexibility and a more favorable kinetic profile than tetraglycosylated FSH. Hypoglycosylated FSH also exhibited stronger binding free energy due to formation of closer and more persistent salt-bridges of both the α- and β-subunits of the variant with the FSHR. Thus, differences in FSH glycosylation appear to influence the stability of FSHR binding, with a more stable FSHR interaction of the hypoglycosylated FSH glycoform relative to the fully (tetra-) glycosylated; these differences in FSH glycoform binding suggest possible mechanisms for the variant biologic effects of fully and partially glycosylated FSH in vivo and in vitro (Walton et al., 2001; Bousfield et al., 2014a; Jiang et al., 2015). Furthermore, the recent model of the FSHR as a functional trimer (see below) (Jiang et al., 2014b) supports in vitro data showing that binding of bulky, fully glycosylated FSH to the FSHR is delayed and occurs at a lower rate compared with that of a more compact, hypoglycosylated variant bearing a high percentage of oligomannose glycans (Bousfield et al., 2014a). In this model, tetraglycosylated FSH with extended glycans would require more time to fit the α52 glycan into the central cavity of the receptor trimer than the hypoglycosylated FSH variant with a more compact glycan structure at this position (Jiang et al., 2014b). This model also may explain the different receptor binding activities and in vitro biologic potency of distinct FSH glycoforms with variations in sialic acid content, in the internal structure of the carbohydrate chains, and in glycan complexity (Ulloa-Aguirre et al., 1995; Creus et al., 2001).

FSHR Self-Association

A number of biochemical, pharmacological, and biophysical studies support the concept of receptor self-association or oligomerization as a fundamental process enabling GPCR activity (Milligan, 2007). Mechanisms of action of G protein-coupled receptors confirm this important issue in different ways. Although some receptors are monomeric at the PM and then associate upon agonist binding and receptor activation, others form dimers or oligomers during synthesis at the endoplasmic reticulum or during processing in the Golgi apparatus. As with many other GPCRs, GPHRs also associate to form homodimers/oligomers and even heterodimers, in which two closely related receptors simultaneously expressed in the same cell [e.g., the LHCGR and FSHR in ovarian mature granulosa cells (Richards et al., 2002)] become associated. A number of studies have shown that the LHCGR and the TSHR do indeed self-associate (Horvat et al., 1999; Latif et al., 2001; Tao et al., 2004; Lei et al., 2007; Kleinau et al., 2013). Although the structure of the FSH-FSHRHB (Fan and Hendrickson, 2005) revealed that the FSHR ectodomain may form weakly associated dimers, with each molecule bearing one FSH molecule, later studies based on combined biochemical and biophysical approaches directly demonstrated that the FSHR self-associates early during receptor biosynthesis and that it can be identified as dimers or oligomers at the plasma membrane (Thomas et al., 2007). Furthermore, this study demonstrated that the carboxyl terminus of the receptor is clipped before trafficking to the plasma membrane (Thomas et al., 2007), a finding that partially explained the paucity of studies on FSHR association because of the difficulties in constructing either functional epitope-tagged FSHRs or FSHR fluorescent fusion proteins at this particular domain. More recently, Mazurkiewicz et al. (2015) overcame this problem by constructing functional chimeras, in which the carboxyl terminus domain of the human WT FSHR was replaced with that of the LHR [which in contrast to the FSHR is not clipped during its biosynthesis (Thomas et al., 2007)] fused with fluorescent proteins (FP). Fluorescence correlation spectroscopy and photon-counting histogram analysis showed that unlike the FSHR-FP, the FSHR-LHR-carboxyl terminus-FP chimera localized to the plasma membrane of transfected live HEK293 cells as a freely diffusing homodimer (Fig. 3, A–C). Using an intensity-based quantitative FRET assay (Elangovan et al., 2003; Wallrabe et al., 2007), Mazurkiewicz et al. (2015) also found that the FSHR-LHR-carboxyl terminus-FP chimera formed homodimers on the cell surface plasma membrane of transfected cells and that upon cotransfection with a WT LHR-fluorescent protein construct, both chimeras formed heterodimers (Fig. 3, D–F). Formation of intracellular FSHR/FSHR and FSHR/LHR complexes may explain the dominant negative effects of FSHR loss-of-function mutants on the plasma membrane expression of either WT FSHR or LHR (Zarinan et al., 2010), which, as shown in other GPCRs (e.g., the gonadotropin-releasing hormone receptor, the TSHR and the V2-vasopressin receptor) might eventually lead to disease (Zhu and Wess, 1998; Ulloa-Aguirre et al., 2004; Calebiro et al., 2005; Leanos-Miranda et al., 2005). Formation of FSHR/FSHR complexes also explains intermolecular complementarity between mutant FSHR dimers, in which function of a hormone binding-deficient FSHR protomer stably expressed in HEK293 cells may be rescued by a signal deficient counterpart after agonist exposure (Ji et al., 2004). Dimerization also explains negative cooperativity between FSHR receptor protomers [i.e., upon ligand binding one protomer blocks or decreases the affinity of the second protomer for its ligand or for intracellular signaling partners leading to a right shift of the dose-response curve (Urizar et al., 2005)], a form of negative dominance at the plasma membrane level. Although this effect may vary according to the cell context, interestingly, in the case of the LHR receptor, complementarity has been documented to also occur in vivo (Rivero-Muller et al., 2010), and this observation may herald important physiologic implications for the gonadotropin receptors. For example, temporal association and alternating negative cooperativity between the FSH and the LH receptors in the ovarian granulosa cells might protect the follicle from premature luteinization or, conversely, from ovarian hyperstimulation, depending on the expression level of each receptor (Yamashita et al., 2005; Feng et al., 2013). Heterozygous mutations that inactivate receptors may remain silent by virtue of WT-receptor rescue effect or may conversely be expressed as adverse clinical manifestations by virtue of the inactive receptor (i.e., with a trafficking defect), preventing the WT receptor from trafficking to the cell surface. The occurrence of homo- and heterodimerization as a mechanism for negative cooperativity between GPHRs (and other GPCRs) represents a unique opportunity for therapeutic interventions. FSHR/LHR heterodimerization is unique to the ovary given that cells expressing these receptors in the testes are located in separate compartments.

Fig. 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 3.

Confocal microscopy of HEK293 cells expressing fluorescent FSHR-ratLHRCtail/FSHR-ratLHRCtail homodimers and FSHR-ratLHRC tail/LHR heterodimers. (A–C) Representative images of HEK293 cells expressing FSHR-ratLHRCtail-yellow fluorescent protein (YFP) and FSHR-ratLHRCtail-mCherry fluorescent protein. (D–F) Representative images of HEK293 cells expressing LHR-YFP and FSHR-ratLHRCtail-mCherry. The images of the merged channels (C and F) demonstrate that FSHR-fluorescent protein chimeras traffic to the plasma membrane (C) and that LHR-YFP traffics to the plasma membrane along with the FSHR-ratLHRCtail-mCherry chimera (D). Quantitative FRET analyses demonstrated that FSHR can form homodimers and FSHR can form a heterodimer with LHR. FRET was detected between these receptor pairs on the plasma membrane with an energy transfer efficiency (E%) of 12.8 ± 1.7 for FSHR homodimers and 14.4 ± 0.8 for the FSHR/LHR heterodimers. In the FRET analysis, the images were loaded into an ImageJ plugin. See the text for additional details. Ctail, carboxyl-terminal tail. Bar = 20 µm.

The mechanism and extent of FSHR self-association is not known, but it seems reasonable to assume that contacts via the α-helices of the TMD play an important role. The more recent crystal structure of the ligand-bound ectodomain of the FSHR, which includes the signal specificity subdomain, demonstrated an additional mode of FSH association with the entire FSHR ectodomain and a quaternary structure bearing three individual ectodomains (i.e., a trimeric receptor structure). This structure predicts hosting of one fully glycosylated FSH molecule or three deglycosylated molecules (Jiang et al., 2014b). In the former scenario, the FSHR may become activated, whereas in the latter, the structure remains inactive, supporting early observations on the lack of effect of deglycosylated FSH in triggering signal transduction at the FSHR (Sairam and Bhargavi, 1985; Sairam, 1989). The trimeric model also explains the reported differences in receptor binding activity between fully glycosylated and hypoglycosylated FSH isoforms, with the former exhibiting delayed and lower binding activities (Bousfield et al., 2014b; Meher et al., 2015). It also suggests a mechanism for FSHR association with multiple proteins and multiple signaling pathways (see below). In contrast with the previously reported structure (Fan and Hendrickson, 2005), Jiang et al. (2014b) structure additionally supports intermolecular associations between the serpentine domains of the protomers, which when associated can only accommodate one Gs protein heterotrimer. In fact, mutational and interfering peptide fragment studies previously suggested that the association between FSHR monomers might occur through the TM domains and/or the carboxyl terminus (Zarinan et al., 2010), as previously demonstrated in the β2-adrenergic receptor (Hebert et al., 1996) and the dopamine D2 receptor homodimerization (Ng et al., 1996; Lee et al., 2003), and the µ- and ∂-opioid receptor hetero-oligomerization (Fan et al., 2005).

Signal Transduction at the FSHR: Multiple Interacting Partners, Signaling Networks, and Functional Selectivity

It is currently accepted that after FSHR activation, a number of intracellular signaling pathways become activated either in parallel or sequentially. The canonical Gsα/cAMP/PKA signaling pathway, which subsequently activates cAMP response element-binding protein, thereby modulating gene transcription, has been recognized for more than two decades as a key effector mechanism of gonadotropin biologic action (Means et al., 1974; Dattatreyamurty et al., 1987; reviewed in Ulloa-Aguirre et al., 2007b). However, in recent years, it has become evident that the FSHR is connected by conformational selectivity to a nonlinear and complex signaling network mediated either by other G protein subtypes, including the Gi, Gq/11, and Gh proteins (Quintana et al., 1994; Arey et al., 1997; Zeleznik et al., 2003; Lin et al., 2006); other types of receptors such as the epidermal growth factor receptor and the insulin-like growth factor 1 receptor (Wayne et al., 2007); and/or particular receptor-associated proteins including β-arrestins and adaptor protein containing the pleckstrin homology domain, the phosphotyrosine binding domain, and the leucine zipper motif (APPL) (Dias et al., 2005, 2010; Kara et al., 2006; Marion et al., 2006; Nechamen et al., 2007; Thomas et al., 2011). These associations promote activation of a number of signaling pathways, including those mediated by distinct kinases such as PKC, PI3K, PKB/Akt, and ERK1/2 (Quintana et al., 1994; Gonzalez-Robayna et al., 2000; Richards et al., 2002; Zeleznik et al., 2003; Kara et al., 2006; Wayne et al., 2007). This complex network of pathways fine tunes the regulation of the FSH stimulus and related ligands (see below), in which the activation/inhibition of its multiple components vary depending on the target cell (e.g., granulosa versus Sertoli cells versus immortalized cell lines), the particular developmental stage of the host cells (e.g., cells from prepubertal versus adult animal donors or in cells from ovarian follicles at different maturation stages), and the receptor and ligand concentration (Crepieux et al., 2001; Richards et al., 2002; Donadeu and Ascoli, 2005; Wayne et al., 2007; Musnier et al., 2009; Casarini et al., 2012; Breen et al., 2013).

The FSHR-mediated pathways triggered by cAMP accumulation independently of PKA activation, such as those activated by the exchange protein directly activated by cAMP, are of particular relevance (Wayne et al., 2007). In addition to cAMP response element-binding protein, cAMP-activated PKA activates p38 mitogen-activated protein kinases, ERK 1/2, p70S6 kinase (p70S6K), and PI3K via insulin receptor substrate 1, which leads to PKB/Akt transactivation (Hunzicker-Dunn et al., 2012; Baumgarten et al., 2014; Law and Hunzicker-Dunn, 2016); exchange protein directly activated by cAMP promotes p38 MAPK and PKB/Akt phosphorylation, and upregulation of the EGFR (Gonzalez-Robayna et al., 2000; Wayne et al., 2007; Choi et al., 2009). As mentioned above, in addition to G proteins, the FSHR also associates with a number of other interacting proteins including the APPL1 and 14-3-3τ adapters and β-arrestin 1 and 2 scaffolds (Cohen et al., 2004; Nechamen et al., 2004; Kara et al., 2006; Nechamen et al., 2007; Dias et al., 2010). Although linking of the FSHR with APPL1 occurs at the receptor intracellular loop 1, particularly at Lys393 (Thomas et al., 2011) (Fig. 1B), association with 14-3-3τ maps to the intracellular loop 2, which overlaps with the canonical G protein binding sites (Cohen et al., 2004; Dias et al., 2010). Follicle-stimulating hormone stimulation rapidly induces FOXO1a phosphorylation in HEK293 cells, leading to repression of apoptosis via either serum and glucocorticoid-induced kinase (Sgk) or APPL1 interaction with the upstream PI3K/Akt pathway (Gonzalez-Robayna et al., 2000; Cunningham et al., 2003; Nechamen et al., 2004). In addition, APPL1 also participates in the FSH-stimulated inositol 1,4,5 triphosphate pathway and is thus implicated in intracellular calcium signaling in granulosa cells (Thomas et al., 2011). The coexistence of APPL1 and 14-3-3τ associated with the FSHR suggests a scenario in which FSH causes phosphorylated FOXO1a to be sequestered by 14-3-3τ with APPL1 to facilitate this antiapoptotic process (Dias et al., 2010).

The FSHR activates ERK1/2 phosphorylation through two distinct pathways, one mediated by Gsα and the other by β-arrestins (Crepieux et al., 2001; Cottom et al., 2003; Kara et al., 2006), which promote desensitization and internalization of the phosphorylated receptor at high levels of receptor occupancy (Ayoub et al., 2015). In addition, these downstream effectors are also involved in the regulation of intracellular signaling via activation of distinct signaling cascades (Reiter and Lefkowitz, 2006). When stimulated by the Gsα-PKA pathway, ERK1/2 phosphorylation occurs via PKA-promoted dissociation of ERK from a 100-kDa phosphotyrosine phosphatase that inhibits ERK activation and its translocation to the nucleus (Cottom et al., 2003). When stimulated by this PKA-mediated pathway, ERK activation occurs early and is transient, peaking 5–10 minutes after FSH exposure, whereas in the Gsα-independent pathway mediated by β-arrestins, it is slower, sustained, and mainly occurs during the ensuing 10–30 minutes after agonist exposure (Kara et al., 2006). As with other GPCRs, the activated FSHR interacts with G protein receptor kinases (GRK), specifically with GRKs 2, 5, and 6 (Troispoux et al., 1999; Kara et al., 2006), which phosphorylate the receptor while simultaneously promoting β-arrestin recruitment (Lazari et al., 1999; Kara et al., 2006). In this regard, a cluster of five serines and threonines (Fig. 1B) at the carboxyl terminus of the FSHR has been shown to account for the bulk of agonist-induced FSHR phosphorylation by GRK2, although GRK5 and 6 also contribute to the same process, but to a lower extent. However, whereas GRK2-phosphorylated FSHR predominates in the β-arrestin-mediated desensitization/internalization process, GRK5- and 6-promoted receptor phosphorylation is required for β-arrestin-dependent, Gsα-independent signaling (Kara et al., 2006; Reiter and Lefkowitz, 2006).

It is currently known that differential or preferential activation of distinct GPCR-mediated signaling cascades may occur through functional selectivity, also referred to as biased agonism, resulting from stabilization of distinct receptor conformations (Venkatakrishnan et al., 2013; Luttrell et al., 2015) by particular ligands or receptor mutations (Wei et al., 2003; Shenoy et al., 2006; Reiter et al., 2012; Luttrell et al., 2015).

In the case of the FSHR, functional selectivity toward Gi-mediated signaling has been documented for some naturally occurring glycosylated variants of human FSH (Timossi et al., 1998; Timossi et al., 2000), in recombinant FSH expressed in insect cells (Arey et al., 1997; Arey and Lopez, 2011), as well as for selective thiazolidinone allosteric compounds with FSH agonist or antagonist properties (Arey et al., 2008). Bias toward β-arrestin-mediated ERK1/2 MAPK signaling has also been observed after exposure to a modified agonist [truncated equine LHβ (Δ121-149) combined with Asn56-deglycosylated equine LHβ] (Wehbi et al., 2010) in HEK293 cells expressing the FSHR; this molecule is particularly interesting because it preferentially activates the β-arrestin-ERK1/2 phosphorylation module, but simultaneously acts as an antagonist of FSH-stimulated cAMP-PKA signaling when tested at equimolar concentrations (Butnev et al., 2002; Wehbi et al., 2010). Recently, Dias et al. (2011) identified a negative allosteric modulator (ADX61623) that increased the affinity of FSH for the FSHR but inactivated FSH-stimulated cAMP and progesterone production, while having no effect on FSH-mediated estrogen production. Interestingly, another negative allosteric modulator [ADX68693 (Dias et al., 2014)] exhibited similar effects on progesterone and estradiol production in vitro and when administered orally to immature female rats, did not block FSH-induced follicle development, which demonstrates the feasibility of applying the concept of biased agonism to in vivo conditions for therapeutic purposes in the reproduction field. At the receptor level, biased agonism has been documented when FSHR plasma membrane expression is severely impaired as a result of a loss-of-function mutation (A189V) (Aittomaki et al., 1996) (Fig. 2); in HEK293 cells, β-arrestins recruited to the agonist-bound FSHR assembled a MAPK module, whereas G protein-dependent signaling remained impaired (Tranchant et al., 2011). Also, expression of the receptor bearing the missense M512I FSHR mutation in HEK293T cells led to an impaired FSH response in terms of cAMP accumulation and PI3K activation but not ERK1/2 phosphorylation (Uchida et al., 2013). A corollary to these findings is that our traditional manner of analyzing the functional impact of structural alterations in ligands and/or receptors should be redesigned to include measurement of multiple readouts by sensitive assays. This may eventually allow further detailed insight into the complex network of signals triggered by FSHR activation and allow us to unambiguously identify the biased effects resulting from such molecular modifications.

Concluding Remarks

The first experimental evidence that the gonads exhibit binding sites specific for FSH was reported in the early 1970s (Means and Vaitukaitis, 1972). Since then, significant progress in the understanding of the structure and function of the FSH/FSHR system has been achieved. Nevertheless, there are still important issues that remain to be resolved. These include the elucidation of the entire structure of the 7 TMD, which undoubtedly will allow a more precise understanding of the mechanisms of receptor activation, oligomerization, and cooperativity, as well as the distinct conformations adopted by the receptor upon association with different ligands, allosteric modulators, and effector proteins. Such knowledge may have important therapeutic implications in the design of potentially useful molecules for the treatment of infertility and in contraception. In this vein, the recently described sequence at the carboxyl-terminal end of the hinge region of all GPHRs that acts as an internal agonist unit after structural changes in the extracellular domain (Fig. 1B) is worth mentioning (Bruser et al., 2016). The possibility of synthesizing related ligands that may be used to modulate ligand-stimulated FSHR activation, particularly in conditions in which receptor mutations lead to promiscuous activation by TSH and/or CG, along with those associated to putative extragonadal effects of FSH, such as menopausal osteoporosis, hyperlipidemia, and tumoral angiogenesis (Radu et al., 2010; Robinson et al., 2010; Sun et al., 2010; Cannon et al., 2011; Siraj et al., 2013; Planeix et al., 2015; Song et al., 2016), could also be considered.

It is also important to continue assembling the complex signaling network and modules that are activated after FSH binding (Gloaguen et al., 2011). This activity provides a suitable testbed for intentional perturbation that may reveal the intracellular mechanisms that control preferential activation of distinct pathways and the crosstalk between different signaling cascades triggered upon FSHR activation. This information can then be further leveraged to understand how the modulation of activation of these pathways governs transcriptional, translational, and posttranslational processes triggered by FSH. Undoubtedly, the application of “omic” technologies, including genomic, transcriptomic, and proteomic techniques, will enormously facilitate this challenging task. In this regard, it seems that the past is just the prologue to what remains to be unveiled.

Acknowledgments

The authors thank George R. Bousfield, Wichita State University, Wichita, KS, and Gunnar Kleinau, Charité-Universitätsmedizin Berlin, Berlin, Germany, for kindly providing Figs. 1 and 2, respectively, and to Joseph E. Mazurkiewicz from Albany Medical College, Albany, NY, for providing Fig. 3. Ilpo Huhtaniemi, Imperial College London, London, England; James A. Dias, University of Albany, Albany, NY; and Gunnar Kleinau, Charité-Universitätsmedizin Berlin, Berlin, Germany, kindly critically read the manuscript. Ari Kleinberg, from the Research Support Network, UNAM, modified Fig. 1 with permission from George R. Bousfield.

Authorship Contributions

Wrote or contributed to the writing of the manuscript: Ulloa-Aguirre, Zariñán.

Footnotes

    • Received March 21, 2016.
    • Accepted June 28, 2016.
  • Research in the authors' laboratory is supported by the Consejo Nacional de Ciencia y Tecnología (CONACyT), Mexico [grant 240619], and the Coordinación de la Investigación Científica, Universidad Nacional autónoma de México (UNAM).

  • dx.doi.org/10.1124/mol.116.104398.

Abbreviations

APPL
adaptor protein containing pleckstrin homology domain, phosphotyrosine binding domain, and leucine zipper motif
FSH
follicle-stimulating hormone
GPH
glycoprotein hormone
GPHR
GPH receptor
GRK
G protein-receptor kinase
HBSD
hormone-binding subdomain
LH
luteinizing hormone
LHR or LHCGR
luteinizing hormone-chorionic gonadotropin receptor
MAPK
mitogen-activated protein kinase
OHSS
ovarian hyperstimulation syndrome
PI3K
phosphoinositide-3 kinase
PKA
protein kinase A
PKB
protein kinase B
TMD
transmembrane domain
TSHR
thyroid-stimulating hormone receptor
WT
wild type
  • Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics

References

  1. ↵
    1. Agrawal G and
    2. Dighe RR
    (2009) Critical involvement of the hinge region of the follicle-stimulating hormone receptor in the activation of the receptor. J Biol Chem 284:2636–2647.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Aittomäki K,
    2. Herva R,
    3. Stenman UH,
    4. Juntunen K,
    5. Ylöstalo P,
    6. Hovatta O, and
    7. de la Chapelle A
    (1996) Clinical features of primary ovarian failure caused by a point mutation in the follicle-stimulating hormone receptor gene. J Clin Endocrinol Metab 81:3722–3726.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Allan CM,
    2. Kalak R,
    3. Dunstan CR,
    4. McTavish KJ,
    5. Zhou H,
    6. Handelsman DJ, and
    7. Seibel MJ
    (2010) Follicle-stimulating hormone increases bone mass in female mice. Proc Natl Acad Sci USA 107:22629–22634.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Allan CM,
    2. Lim P,
    3. Robson M,
    4. Spaliviero J, and
    5. Handelsman DJ
    (2009) Transgenic mutant D567G but not wild-type human FSH receptor overexpression provides FSH-independent and promiscuous glycoprotein hormone Sertoli cell signaling. Am J Physiol Endocrinol Metab 296:E1022–E1028.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Arey BJ and
    2. López FJ
    (2011) Are circulating gonadotropin isoforms naturally occurring biased agonists? Basic and therapeutic implications. Rev Endocr Metab Disord 12:275–288.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Arey BJ,
    2. Stevis PE,
    3. Deecher DC,
    4. Shen ES,
    5. Frail DE,
    6. Negro-Vilar A, and
    7. Lopez FJ
    (1997) Induction of promiscuous G protein coupling of the follicle-stimulating hormone (FSH) receptor: a novel mechanism for transducing pleiotropic actions of FSH isoforms. Mol Endocrinol 11:517–526.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Arey BJ,
    2. Yanofsky SD,
    3. Claudia Pérez M,
    4. Holmes CP,
    5. Wrobel J,
    6. Gopalsamy A,
    7. Stevis PE,
    8. López FJ, and
    9. Winneker RC
    (2008) Differing pharmacological activities of thiazolidinone analogs at the FSH receptor. Biochem Biophys Res Commun 368:723–728.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Ayoub MA,
    2. Landomiel F,
    3. Gallay N,
    4. Jégot G,
    5. Poupon A,
    6. Crépieux P, and
    7. Reiter E
    (2015) Assessing Gonadotropin Receptor Function by Resonance Energy Transfer-Based Assays. Front Endocrinol (Lausanne) 6:130.
    OpenUrlPubMed
  9. ↵
    1. Babu PS,
    2. Danilovich N, and
    3. Sairam MR
    (2001) Hormone-induced receptor gene splicing: enhanced expression of the growth factor type I follicle-stimulating hormone receptor motif in the developing mouse ovary as a new paradigm in growth regulation. Endocrinology 142:381–389.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Babu PS,
    2. Jiang L,
    3. Sairam AM,
    4. Touyz RM, and
    5. Sairam MR
    (1999) Structural features and expression of an alternatively spliced growth factor type I receptor for follitropin signaling in the developing ovary. Mol Cell Biol Res Commun 2:21–27.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Babu PS,
    2. Krishnamurthy H,
    3. Chedrese PJ, and
    4. Sairam MR
    (2000) Activation of extracellular-regulated kinase pathways in ovarian granulosa cells by the novel growth factor type 1 follicle-stimulating hormone receptor. Role in hormone signaling and cell proliferation. J Biol Chem 275:27615–27626.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Banerjee AA,
    2. Dupakuntla M,
    3. Pathak BR, and
    4. Mahale SD
    (2015) FSH receptor-specific residues L501 and I505 in extracellular loop 2 are essential for its function. J Mol Endocrinol 54:193–204.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Barrios-De-Tomasi J,
    2. Timossi C,
    3. Merchant H,
    4. Quintanar A,
    5. Avalos JM,
    6. Andersen CY, and
    7. Ulloa-Aguirre A
    (2002) Assessment of the in vitro and in vivo biological activities of the human follicle-stimulating isohormones. Mol Cell Endocrinol 186:189–198.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Baumgarten SC,
    2. Convissar SM,
    3. Fierro MA,
    4. Winston NJ,
    5. Scoccia B, and
    6. Stocco C
    (2014) IGF1R signaling is necessary for FSH-induced activation of AKT and differentiation of human Cumulus granulosa cells. J Clin Endocrinol Metab 99:2995–3004.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Bogerd J
    (2007) Ligand-selective determinants in gonadotropin receptors. Mol Cell Endocrinol 260-262:144–152.
    OpenUrl
  16. ↵
    1. Bonomi M,
    2. Busnelli M,
    3. Persani L,
    4. Vassart G, and
    5. Costagliola S
    (2006) Structural differences in the hinge region of the glycoprotein hormone receptors: evidence from the sulfated tyrosine residues. Mol Endocrinol 20:3351–3363.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Bousfield GR,
    2. Butnev VY,
    3. Butnev VY,
    4. Hiromasa Y,
    5. Harvey DJ, and
    6. May JV
    (2014a) Hypo-glycosylated human follicle-stimulating hormone (hFSH(21/18)) is much more active in vitro than fully-glycosylated hFSH (hFSH(24)). Mol Cell Endocrinol 382:989–997.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Bousfield GR,
    2. Butnev VY,
    3. Gotschall RR,
    4. Baker VL, and
    5. Moore WT
    (1996) Structural features of mammalian gonadotropins. Mol Cell Endocrinol 125:3–19.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Bousfield GR,
    2. Butnev VY,
    3. Rueda-Santos MA,
    4. Brown A,
    5. Hall AS, and
    6. Harvey DJ
    (2014b) Macro- and Micro-heterogeneity in Pituitary and Urinary Follicle-Stimulating Hormone Glycosylation. J Glycomics Lipidomics 4:1000125.
    OpenUrlPubMed
  20. ↵
    1. Bousfield GR,
    2. Butnev VY,
    3. White WK,
    4. Hall AS, and
    5. Harvey DJ
    (2015) Comparison of follicle-stimulating hormone glycosylation microheterogenity by quantitative negative mode nano-electrospray mass spectrometry of peptide-N glycanase-released oligosaccharides. J Glycomics Lipidomics 5:129.
    OpenUrlPubMed
  21. ↵
    1. Bramble MS,
    2. Goldstein EH,
    3. Lipson A,
    4. Ngun T,
    5. Eskin A,
    6. Gosschalk JE,
    7. Roach L,
    8. Vashist N,
    9. Barseghyan H,
    10. Lee E,
    11. et al.
    (2016) A novel follicle-stimulating hormone receptor mutation causing primary ovarian failure: a fertility application of whole exome sequencing. Hum Reprod 31:905–914.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Breen SM,
    2. Andric N,
    3. Ping T,
    4. Xie F,
    5. Offermans S,
    6. Gossen JA, and
    7. Ascoli M
    (2013) Ovulation involves the luteinizing hormone-dependent activation of G(q/11) in granulosa cells. Mol Endocrinol 27:1483–1491.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Brüser A,
    2. Schulz A,
    3. Rothemund S,
    4. Ricken A,
    5. Calebiro D,
    6. Kleinau G, and
    7. Schöneberg T
    (2016) The activation mechanism of glycoprotein hormone receptors with implications in the cause and therapy of endocrine diseases. J Biol Chem 291:508–520.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Bruysters M,
    2. Verhoef-Post M, and
    3. Themmen AP
    (2008) Asp330 and Tyr331 in the C-terminal cysteine-rich region of the luteinizing hormone receptor are key residues in hormone-induced receptor activation. J Biol Chem 283:25821–25828.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Butnev VY,
    2. Butnev VY,
    3. May JV,
    4. Shuai B,
    5. Tran P,
    6. White WK,
    7. Brown A,
    8. Smalter Hall A,
    9. Harvey DJ, and
    10. Bousfield GR
    (2015) Production, purification, and characterization of recombinant hFSH glycoforms for functional studies. Mol Cell Endocrinol 405:42–51.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Butnev VY,
    2. Singh V,
    3. Nguyen VT, and
    4. Bousfield GR
    (2002) Truncated equine LH beta and asparagine(56)-deglycosylated equine LH alpha combine to produce a potent FSH antagonist. J Endocrinol 172:545–555.
    OpenUrlAbstract
  27. ↵
    1. Calebiro D,
    2. de Filippis T,
    3. Lucchi S,
    4. Covino C,
    5. Panigone S,
    6. Beck-Peccoz P,
    7. Dunlap D, and
    8. Persani L
    (2005) Intracellular entrapment of wild-type TSH receptor by oligomerization with mutants linked to dominant TSH resistance. Hum Mol Genet 14:2991–3002.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Cannon JG,
    2. Kraj B, and
    3. Sloan G
    (2011) Follicle-stimulating hormone promotes RANK expression on human monocytes. Cytokine 53:141–144.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Casarini L,
    2. Lispi M,
    3. Longobardi S,
    4. Milosa F,
    5. La Marca A,
    6. Tagliasacchi D,
    7. Pignatti E, and
    8. Simoni M
    (2012) LH and hCG action on the same receptor results in quantitatively and qualitatively different intracellular signalling. PLoS One 7:e46682.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Casas-González P,
    2. Scaglia HE,
    3. Pérez-Solís MA,
    4. Durand G,
    5. Scaglia J,
    6. Zariñán T,
    7. Dias JA,
    8. Reiter E, and
    9. Ulloa-Aguirre A
    (2012) Normal testicular function without detectable follicle-stimulating hormone. A novel mutation in the follicle-stimulating hormone receptor gene leading to apparent constitutive activity and impaired agonist-induced desensitization and internalization. Mol Cell Endocrinol 364:71–82.
    OpenUrlCrossRefPubMed
  31. ↵
    1. Chen CR,
    2. Chazenbalk GD,
    3. McLachlan SM, and
    4. Rapoport B
    (2003) Evidence that the C terminus of the A subunit suppresses thyrotropin receptor constitutive activity. Endocrinology 144:3821–3827.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Choi JH,
    2. Chen CL,
    3. Poon SL,
    4. Wang HS, and
    5. Leung PC
    (2009) Gonadotropin-stimulated epidermal growth factor receptor expression in human ovarian surface epithelial cells: involvement of cyclic AMP-dependent exchange protein activated by cAMP pathway. Endocr Relat Cancer 16:179–188.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    1. Cohen BD,
    2. Nechamen CA, and
    3. Dias JA
    (2004) Human follitropin receptor (FSHR) interacts with the adapter protein 14-3-3tau. Mol Cell Endocrinol 220:1–7.
    OpenUrlCrossRefPubMed
  34. ↵
    1. Costagliola S,
    2. Panneels V,
    3. Bonomi M,
    4. Koch J,
    5. Many MC,
    6. Smits G, and
    7. Vassart G
    (2002) Tyrosine sulfation is required for agonist recognition by glycoprotein hormone receptors. EMBO J 21:504–513.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Cottom J,
    2. Salvador LM,
    3. Maizels ET,
    4. Reierstad S,
    5. Park Y,
    6. Carr DW,
    7. Davare MA,
    8. Hell JW,
    9. Palmer SS,
    10. Dent P,
    11. et al.
    (2003) Follicle-stimulating hormone activates extracellular signal-regulated kinase but not extracellular signal-regulated kinase kinase through a 100-kDa phosphotyrosine phosphatase. J Biol Chem 278:7167–7179.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    1. Crépieux P,
    2. Marion S,
    3. Martinat N,
    4. Fafeur V,
    5. Vern YL,
    6. Kerboeuf D,
    7. Guillou F, and
    8. Reiter E
    (2001) The ERK-dependent signalling is stage-specifically modulated by FSH, during primary Sertoli cell maturation. Oncogene 20:4696–4709.
    OpenUrlCrossRefPubMed
  37. ↵
    1. Creus S,
    2. Chaia Z,
    3. Pellizzari EH,
    4. Cigorraga SB,
    5. Ulloa-Aguirre A, and
    6. Campo S
    (2001) Human FSH isoforms: carbohydrate complexity as determinant of in-vitro bioactivity. Mol Cell Endocrinol 174:41–49.
    OpenUrlCrossRefPubMed
  38. ↵
    1. Cunningham MA,
    2. Zhu Q,
    3. Unterman TG, and
    4. Hammond JM
    (2003) Follicle-stimulating hormone promotes nuclear exclusion of the forkhead transcription factor FoxO1a via phosphatidylinositol 3-kinase in porcine granulosa cells. Endocrinology 144:5585–5594.
    OpenUrlCrossRefPubMed
  39. ↵
    1. Dattatreyamurty B,
    2. Figgs LW, and
    3. Reichert LE Jr.
    (1987) Physical and functional association of follitropin receptors with cholera toxin-sensitive guanine nucleotide-binding protein. J Biol Chem 262:11737–11745.
    OpenUrlAbstract/FREE Full Text
  40. ↵
    1. De Leener A,
    2. Caltabiano G,
    3. Erkan S,
    4. Idil M,
    5. Vassart G,
    6. Pardo L, and
    7. Costagliola S
    (2008) Identification of the first germline mutation in the extracellular domain of the follitropin receptor responsible for spontaneous ovarian hyperstimulation syndrome. Hum Mutat 29:91–98.
    OpenUrlCrossRefPubMed
  41. ↵
    1. De Leener A,
    2. Montanelli L,
    3. Van Durme J,
    4. Chae H,
    5. Smits G,
    6. Vassart G, and
    7. Costagliola S
    (2006) Presence and absence of follicle-stimulating hormone receptor mutations provide some insights into spontaneous ovarian hyperstimulation syndrome physiopathology. J Clin Endocrinol Metab 91:555–562.
    OpenUrlCrossRefPubMed
  42. ↵
    1. Desai SS,
    2. Achrekar SK,
    3. Sahasrabuddhe KA,
    4. Meharji PK,
    5. Desai SK,
    6. Mangoli VS, and
    7. Mahale SD
    (2015) Functional characterization of two naturally occurring mutations (Val514Ala and Ala575Val) in follicle-stimulating hormone receptor. J Clin Endocrinol Metab 100:E638–E645.
    OpenUrlCrossRefPubMed
  43. ↵
    1. Desai SS,
    2. Roy BS, and
    3. Mahale SD
    (2013) Mutations and polymorphisms in FSH receptor: functional implications in human reproduction. Reproduction 146:R235–R248.
    OpenUrlAbstract/FREE Full Text
  44. ↵
    1. Dias JA
    (2005) Endocrinology: fertility hormone in repose. Nature 433:203–204.
    OpenUrlCrossRefPubMed
  45. ↵
    1. Dias JA,
    2. Bonnet B,
    3. Weaver BA,
    4. Watts J,
    5. Kluetzman K,
    6. Thomas RM,
    7. Poli S,
    8. Mutel V, and
    9. Campo B
    (2011) A negative allosteric modulator demonstrates biased antagonism of the follicle stimulating hormone receptor. Mol Cell Endocrinol 333:143–150.
    OpenUrlCrossRefPubMed
  46. ↵
    1. Dias JA,
    2. Campo B,
    3. Weaver BA,
    4. Watts J,
    5. Kluetzman K,
    6. Thomas RM,
    7. Bonnet B,
    8. Mutel V, and
    9. Poli SM
    (2014) Inhibition of follicle-stimulating hormone-induced preovulatory follicles in rats treated with a nonsteroidal negative allosteric modulator of follicle-stimulating hormone receptor. Biol Reprod 90:19.
    OpenUrlAbstract/FREE Full Text
  47. ↵
    1. Dias JA,
    2. Cohen BD,
    3. Lindau-Shepard B,
    4. Nechamen CA,
    5. Peterson AJ, and
    6. Schmidt A
    (2002) Molecular, structural, and cellular biology of follitropin and follitropin receptor. Vitam Horm 64:249–322.
    OpenUrlCrossRefPubMed
  48. ↵
    1. Dias JA,
    2. Mahale SD,
    3. Nechamen CA,
    4. Davydenko O,
    5. Thomas RM, and
    6. Ulloa-Aguirre A
    (2010) Emerging roles for the FSH receptor adapter protein APPL1 and overlap of a putative 14-3-3τ interaction domain with a canonical G-protein interaction site. Mol Cell Endocrinol 329:17–25.
    OpenUrlCrossRefPubMed
  49. ↵
    1. Dias JA,
    2. Nechamen CA, and
    3. Atari R
    (2005) Identifying protein interactors in gonadotropin action. Endocrine 26:241–247.
    OpenUrlCrossRefPubMed
  50. ↵
    1. Dias JA and
    2. Van Roey P
    (2001) Structural biology of human follitropin and its receptor. Arch Med Res 32:510–519.
    OpenUrlCrossRefPubMed
  51. ↵
    1. Donadeu FX and
    2. Ascoli M
    (2005) The differential effects of the gonadotropin receptors on aromatase expression in primary cultures of immature rat granulosa cells are highly dependent on the density of receptors expressed and the activation of the inositol phosphate cascade. Endocrinology 146:3907–3916.
    OpenUrlCrossRefPubMed
  52. ↵
    1. Dupakuntla M and
    2. Mahale SD
    (2010) Accessibility of the extracellular loops of follicle stimulating hormone receptor and their role in hormone-receptor interaction. Mol Cell Endocrinol 315:131–137.
    OpenUrlCrossRefPubMed
  53. ↵
    1. Dupakuntla M,
    2. Pathak B,
    3. Roy BS, and
    4. Mahale SD
    (2012) Extracellular loop 2 in the FSH receptor is crucial for ligand mediated receptor activation. Mol Cell Endocrinol 362:60–68.
    OpenUrlCrossRefPubMed
  54. ↵
    1. Duvernay MT,
    2. Zhou F, and
    3. Wu G
    (2004) A conserved motif for the transport of G protein-coupled receptors from the endoplasmic reticulum to the cell surface. J Biol Chem 279:30741–30750.
    OpenUrlAbstract/FREE Full Text
  55. ↵
    1. Elangovan M,
    2. Wallrabe H,
    3. Chen Y,
    4. Day RN,
    5. Barroso M, and
    6. Periasamy A
    (2003) Characterization of one- and two-photon excitation fluorescence resonance energy transfer microscopy. Methods 29:58–73.
    OpenUrlCrossRefPubMed
  56. ↵
    1. Fan QR and
    2. Hendrickson WA
    (2005) Structure of human follicle-stimulating hormone in complex with its receptor. Nature 433:269–277.
    OpenUrlCrossRefPubMed
  57. ↵
    1. Fan QR and
    2. Hendrickson WA
    (2007) Assembly and structural characterization of an authentic complex between human follicle stimulating hormone and a hormone-binding ectodomain of its receptor. Mol Cell Endocrinol 260-262:73–82.
    OpenUrl
  58. ↵
    1. Fan T,
    2. Varghese G,
    3. Nguyen T,
    4. Tse R,
    5. O’Dowd BF, and
    6. George SR
    (2005) A role for the distal carboxyl tails in generating the novel pharmacology and G protein activation profile of mu and delta opioid receptor hetero-oligomers. J Biol Chem 280:38478–38488.
    OpenUrlAbstract/FREE Full Text
  59. ↵
    1. Feng X,
    2. Zhang M,
    3. Guan R, and
    4. Segaloff DL
    (2013) Heterodimerization between the lutropin and follitropin receptors is associated with an attenuation of hormone-dependent signaling. Endocrinology 154:3925–3930.
    OpenUrlCrossRefPubMed
  60. ↵
    1. Flack MR,
    2. Froehlich J,
    3. Bennet AP,
    4. Anasti J, and
    5. Nisula BC
    (1994) Site-directed mutagenesis defines the individual roles of the glycosylation sites on follicle-stimulating hormone. J Biol Chem 269:14015–14020.
    OpenUrlAbstract/FREE Full Text
  61. ↵
    1. Fox KM,
    2. Dias JA, and
    3. Van Roey P
    (2001) Three-dimensional structure of human follicle-stimulating hormone. Mol Endocrinol 15:378–389.
    OpenUrlCrossRefPubMed
  62. ↵
    1. Gao J,
    2. Tiwari-Pandey R,
    3. Samadfam R,
    4. Yang Y,
    5. Miao D,
    6. Karaplis AC,
    7. Sairam MR, and
    8. Goltzman D
    (2007) Altered ovarian function affects skeletal homeostasis independent of the action of follicle-stimulating hormone. Endocrinology 148:2613–2621.
    OpenUrlCrossRefPubMed
  63. ↵
    1. Gerasimova T,
    2. Thanasoula MN,
    3. Zattas D,
    4. Seli E,
    5. Sakkas D, and
    6. Lalioti MD
    (2010) Identification and in vitro characterization of follicle stimulating hormone (FSH) receptor variants associated with abnormal ovarian response to FSH. J Clin Endocrinol Metab 95:529–536.
    OpenUrlCrossRefPubMed
  64. ↵
    1. Gloaguen P,
    2. Crépieux P,
    3. Heitzler D,
    4. Poupon A, and
    5. Reiter E
    (2011) Mapping the follicle-stimulating hormone-induced signaling networks. Front Endocrinol (Lausanne) 2:45.
    OpenUrlPubMed
  65. ↵
    1. Gonzalez-Robayna IJ,
    2. Falender AE,
    3. Ochsner S,
    4. Firestone GL, and
    5. Richards JS
    (2000) Follicle-stimulating hormone (FSH) stimulates phosphorylation and activation of protein kinase B (PKB/Akt) and serum and glucocorticoid-lnduced kinase (Sgk): evidence for A kinase-independent signaling by FSH in granulosa cells. Mol Endocrinol 14:1283–1300.
    OpenUrlCrossRefPubMed
  66. ↵
    1. Gromoll J,
    2. Dankbar B,
    3. Sharma RS, and
    4. Nieschlag E
    (1993) Molecular cloning of the testicular follicle stimulating hormone receptor of the non human primate Macaca fascicularis and identification of multiple transcripts in the testis. Biochem Biophys Res Commun 196:1066–1072.
    OpenUrlCrossRefPubMed
  67. ↵
    1. Gromoll J,
    2. Pekel E, and
    3. Nieschlag E
    (1996) The structure and organization of the human follicle-stimulating hormone receptor (FSHR) gene. Genomics 35:308–311.
    OpenUrlCrossRefPubMed
  68. ↵
    1. Gromoll J,
    2. Ried T,
    3. Holtgreve-Grez H,
    4. Nieschlag E, and
    5. Gudermann T
    (1994) Localization of the human FSH receptor to chromosome 2 p21 using a genomic probe comprising exon 10. J Mol Endocrinol 12:265–271.
    OpenUrlAbstract/FREE Full Text
  69. ↵
    1. Hebert TE,
    2. Moffett S,
    3. Morello JP,
    4. Loisel TP,
    5. Bichet DG,
    6. Barret C, and
    7. Bouvier M
    (1996) A peptide derived from a beta2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation. J Biol Chem 271:16384–16392.
    OpenUrlAbstract/FREE Full Text
  70. ↵
    1. Horvat RD,
    2. Nelson S,
    3. Clay CM,
    4. Barisas BG, and
    5. Roess DA
    (1999) Intrinsically fluorescent luteinizing hormone receptor demonstrates hormone-driven aggregation. Biochem Biophys Res Commun 255:382–385.
    OpenUrlCrossRefPubMed
  71. ↵
    1. Huhtaniemi IT,
    2. Clayton RN, and
    3. Catt KJ
    (1982) Gonadotropin binding and Leydig cell activation in the rat testis in vivo. Endocrinology 111:982–987.
    OpenUrlCrossRefPubMed
  72. ↵
    1. Hunzicker-Dunn ME,
    2. Lopez-Biladeau B,
    3. Law NC,
    4. Fiedler SE,
    5. Carr DW, and
    6. Maizels ET
    (2012) PKA and GAB2 play central roles in the FSH signaling pathway to PI3K and AKT in ovarian granulosa cells. Proc Natl Acad Sci USA 109:E2979–E2988.
    OpenUrlAbstract/FREE Full Text
  73. ↵
    1. Ji I and
    2. Ji TH
    (1995) Differential roles of exoloop 1 of the human follicle-stimulating hormone receptor in hormone binding and receptor activation. J Biol Chem 270:15970–15973.
    OpenUrlAbstract/FREE Full Text
  74. ↵
    1. Ji I,
    2. Lee C,
    3. Jeoung M,
    4. Koo Y,
    5. Sievert GA, and
    6. Ji TH
    (2004) Trans-activation of mutant follicle-stimulating hormone receptors selectively generates only one of two hormone signals. Mol Endocrinol 18:968–978.
    OpenUrlCrossRefPubMed
  75. ↵
    1. Jiang C,
    2. Hou X,
    3. Wang C,
    4. May JV,
    5. Butnev VY,
    6. Bousfield GR, and
    7. Davis JS
    (2015) Hypoglycosylated hFSH has greater bioactivity than fully glycosylated recombinant hFSH in human granulosa cells. J Clin Endocrinol Metab 100:E852–E860.
    OpenUrlCrossRefPubMed
  76. ↵
    1. Jiang X,
    2. Dias JA, and
    3. He X
    (2014a) Structural biology of glycoprotein hormones and their receptors: insights to signaling. Mol Cell Endocrinol 382:424–451.
    OpenUrlCrossRefPubMed
  77. ↵
    1. Jiang X,
    2. Dreano M,
    3. Buckler DR,
    4. Cheng S,
    5. Ythier A,
    6. Wu H,
    7. Hendrickson WA, and
    8. el Tayar N
    (1995) Structural predictions for the ligand-binding region of glycoprotein hormone receptors and the nature of hormone-receptor interactions. Structure 3:1341–1353.
    OpenUrlCrossRefPubMed
  78. ↵
    1. Jiang X,
    2. Fischer D,
    3. Chen X,
    4. McKenna SD,
    5. Liu H,
    6. Sriraman V,
    7. Yu HN,
    8. Goutopoulos A,
    9. Arkinstall S, and
    10. He X
    (2014b) Evidence for Follicle-stimulating Hormone Receptor as a Functional Trimer. J Biol Chem 289:14273–14282.
    OpenUrlAbstract/FREE Full Text
  79. ↵
    1. Jiang X,
    2. Liu H,
    3. Chen X,
    4. Chen PH,
    5. Fischer D,
    6. Sriraman V,
    7. Yu HN,
    8. Arkinstall S, and
    9. He X
    (2012) Structure of follicle-stimulating hormone in complex with the entire ectodomain of its receptor. Proc Natl Acad Sci USA 109:12491–12496.
    OpenUrlAbstract/FREE Full Text
  80. ↵
    1. Kara E,
    2. Crépieux P,
    3. Gauthier C,
    4. Martinat N,
    5. Piketty V,
    6. Guillou F, and
    7. Reiter E
    (2006) A phosphorylation cluster of five serine and threonine residues in the C-terminus of the follicle-stimulating hormone receptor is important for desensitization but not for beta-arrestin-mediated ERK activation. Mol Endocrinol 20:3014–3026.
    OpenUrlCrossRefPubMed
  81. ↵
    1. Karakaya C,
    2. Guzeloglu-Kayisli O,
    3. Hobbs RJ,
    4. Gerasimova T,
    5. Uyar A,
    6. Erdem M,
    7. Oktem M,
    8. Erdem A,
    9. Gumuslu S,
    10. Ercan D,
    11. et al.
    (2014) Follicle-stimulating hormone receptor (FSHR) alternative skipping of exon 2 or 3 affects ovarian response to FSH. Mol Hum Reprod 20:630–643.
    OpenUrlAbstract/FREE Full Text
  82. ↵
    1. Kelton CA,
    2. Cheng SV,
    3. Nugent NP,
    4. Schweickhardt RL,
    5. Rosenthal JL,
    6. Overton SA,
    7. Wands GD,
    8. Kuzeja JB,
    9. Luchette CA, and
    10. Chappel SC
    (1992) The cloning of the human follicle stimulating hormone receptor and its expression in COS-7, CHO, and Y-1 cells. Mol Cell Endocrinol 89:141–151.
    OpenUrlCrossRefPubMed
  83. ↵
    1. Khan H,
    2. Yarney TA, and
    3. Sairam MR
    (1993) Cloning of alternately spliced mRNA transcripts coding for variants of ovine testicular follitropin receptor lacking the G protein coupling domains. Biochem Biophys Res Commun 190:888–894.
    OpenUrlCrossRefPubMed
  84. ↵
    1. Kleinau G,
    2. Claus M,
    3. Jaeschke H,
    4. Mueller S,
    5. Neumann S,
    6. Paschke R, and
    7. Krause G
    (2007) Contacts between extracellular loop two and transmembrane helix six determine basal activity of the thyroid-stimulating hormone receptor. J Biol Chem 282:518–525.
    OpenUrlAbstract/FREE Full Text
  85. ↵
    1. Kleinau G and
    2. Krause G
    (2009) Thyrotropin and homologous glycoprotein hormone receptors: structural and functional aspects of extracellular signaling mechanisms. Endocr Rev 30:133–151.
    OpenUrlCrossRefPubMed
  86. ↵
    1. Kleinau G,
    2. Neumann S,
    3. Grüters A,
    4. Krude H, and
    5. Biebermann H
    (2013) Novel insights on thyroid-stimulating hormone receptor signal transduction. Endocr Rev 34:691–724.
    OpenUrlCrossRefPubMed
  87. ↵
    1. Kudo M,
    2. Osuga Y,
    3. Kobilka BK, and
    4. Hsueh AJ
    (1996) Transmembrane regions V and VI of the human luteinizing hormone receptor are required for constitutive activation by a mutation in the third intracellular loop. J Biol Chem 271:22470–22478.
    OpenUrlAbstract/FREE Full Text
  88. ↵
    1. Kumar P,
    2. Sait SF,
    3. Sharma A, and
    4. Kumar M
    (2011) Ovarian hyperstimulation syndrome. J Hum Reprod Sci 4:70–75.
    OpenUrlCrossRefPubMed
  89. ↵
    1. Latif R,
    2. Graves P, and
    3. Davies TF
    (2001) Oligomerization of the human thyrotropin receptor: fluorescent protein-tagged hTSHR reveals post-translational complexes. J Biol Chem 276:45217–45224.
    OpenUrlAbstract/FREE Full Text
  90. ↵
    1. Law NC and
    2. Hunzicker-Dunn ME
    (2016) Insulin receptor substrate 1, the hub linking follicle-stimulating hormone to phosphatidylinositol 3-kinase activation. J Biol Chem 291:4547–4560.
    OpenUrlAbstract/FREE Full Text
  91. ↵
    1. Lazari MF,
    2. Liu X,
    3. Nakamura K,
    4. Benovic JL, and
    5. Ascoli M
    (1999) Role of G protein-coupled receptor kinases on the agonist-induced phosphorylation and internalization of the follitropin receptor. Mol Endocrinol 13:866–878.
    OpenUrlCrossRefPubMed
  92. ↵
    1. Leaños-Miranda A,
    2. Ulloa-Aguirre A,
    3. Janovick JA, and
    4. Conn PM
    (2005) In vitro coexpression and pharmacological rescue of mutant gonadotropin-releasing hormone receptors causing hypogonadotropic hypogonadism in humans expressing compound heterozygous alleles. J Clin Endocrinol Metab 90:3001–3008.
    OpenUrlCrossRefPubMed
  93. ↵
    1. Lee SP,
    2. O’Dowd BF,
    3. Rajaram RD,
    4. Nguyen T, and
    5. George SR
    (2003) D2 dopamine receptor homodimerization is mediated by multiple sites of interaction, including an intermolecular interaction involving transmembrane domain 4. Biochemistry 42:11023–11031.
    OpenUrlCrossRefPubMed
  94. ↵
    1. Lei Y,
    2. Hagen GM,
    3. Smith SM,
    4. Liu J,
    5. Barisas G, and
    6. Roess DA
    (2007) Constitutively-active human LH receptors are self-associated and located in rafts. Mol Cell Endocrinol 260-262:65–72.
    OpenUrl
  95. ↵
    1. Lin YF,
    2. Tseng MJ,
    3. Hsu HL,
    4. Wu YW,
    5. Lee YH, and
    6. Tsai YH
    (2006) A novel follicle-stimulating hormone-induced G alpha h/phospholipase C-delta1 signaling pathway mediating rat sertoli cell Ca2+-influx. Mol Endocrinol 20:2514–2527.
    OpenUrlCrossRefPubMed
  96. ↵
    1. Luttrell LM,
    2. Maudsley S, and
    3. Bohn LM
    (2015) Fulfilling the promise of “biased” G protein-coupled receptor agonism. Mol Pharmacol 88:579–588.
    OpenUrlAbstract/FREE Full Text
  97. ↵
    1. Marion S,
    2. Kara E,
    3. Crepieux P,
    4. Piketty V,
    5. Martinat N,
    6. Guillou F, and
    7. Reiter E
    (2006) G protein-coupled receptor kinase 2 and beta-arrestins are recruited to FSH receptor in stimulated rat primary Sertoli cells. J Endocrinol 190:341–350.
    OpenUrlAbstract/FREE Full Text
  98. ↵
    1. Matzuk MM and
    2. Boime I
    (1989) Mutagenesis and gene transfer define site-specific roles of the gonadotropin oligosaccharides. Biol Reprod 40:48–53.
    OpenUrlAbstract
  99. ↵
    1. Matzuk MM,
    2. Keene JL, and
    3. Boime I
    (1989) Site specificity of the chorionic gonadotropin N-linked oligosaccharides in signal transduction. J Biol Chem 264:2409–2414.
    OpenUrlAbstract/FREE Full Text
  100. ↵
    1. Mazurkiewicz JE,
    2. Herrick-Davis K,
    3. Barroso M,
    4. Ulloa-Aguirre A,
    5. Lindau-Shepard B,
    6. Thomas RM, and
    7. Dias JA
    (2015) Single-molecule analyses of fully functional fluorescent protein-tagged follitropin receptor reveal homodimerization and specific heterodimerization with lutropin receptor. Biol Reprod 92:100.
    OpenUrlAbstract/FREE Full Text
  101. ↵
    1. Means AR,
    2. MacDougall E,
    3. Soderling TR, and
    4. Corbin JD
    (1974) Testicular adenosine 3′:5′-monophosphate-dependent protein kinase. Regulation by follicle-stimulating hormone. J Biol Chem 249:1231–1238.
    OpenUrlAbstract/FREE Full Text
  102. ↵
    1. Means AR and
    2. Vaitukaitis J
    (1972) Peptide hormone “receptors”: specific binding of 3 H-FSH to testis. Endocrinology 90:39–46.
    OpenUrlCrossRefPubMed
  103. ↵
    1. Meher BR,
    2. Dixit A,
    3. Bousfield GR, and
    4. Lushington GH
    (2015) Glycosylation effects on FSH-FSHR interaction dynamics: a case study of different FSH glycoforms by molecular dynamics simulations. PLoS One 10:e0137897.
    OpenUrlCrossRefPubMed
  104. ↵
    1. Milligan G
    (2007) G protein-coupled receptor dimerisation: molecular basis and relevance to function. Biochim Biophys Acta 1768:825–835.
    OpenUrlCrossRefPubMed
  105. ↵
    1. Montanelli L,
    2. Delbaere A,
    3. Di Carlo C,
    4. Nappi C,
    5. Smits G,
    6. Vassart G, and
    7. Costagliola S
    (2004a) A mutation in the follicle-stimulating hormone receptor as a cause of familial spontaneous ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 89:1255–1258.
    OpenUrlCrossRefPubMed
  106. ↵
    1. Montanelli L,
    2. Van Durme JJ,
    3. Smits G,
    4. Bonomi M,
    5. Rodien P,
    6. Devor EJ,
    7. Moffat-Wilson K,
    8. Pardo L,
    9. Vassart G, and
    10. Costagliola S
    (2004b) Modulation of ligand selectivity associated with activation of the transmembrane region of the human follitropin receptor. Mol Endocrinol 18:2061–2073.
    OpenUrlCrossRefPubMed
  107. ↵
    1. Mueller S,
    2. Jaeschke H,
    3. Günther R, and
    4. Paschke R
    (2010) The hinge region: an important receptor component for GPHR function. Trends Endocrinol Metab 21:111–122.
    OpenUrlCrossRefPubMed
  108. ↵
    1. Musnier A,
    2. Heitzler D,
    3. Boulo T,
    4. Tesseraud S,
    5. Durand G,
    6. Lécureuil C,
    7. Guillou H,
    8. Poupon A,
    9. Reiter E, and
    10. Crépieux P
    (2009) Developmental regulation of p70 S6 kinase by a G protein-coupled receptor dynamically modelized in primary cells. Cell Mol Life Sci 66:3487–3503.
    OpenUrlCrossRefPubMed
  109. ↵
    1. Nakabayashi K,
    2. Kudo M,
    3. Kobilka B, and
    4. Hsueh AJ
    (2000) Activation of the luteinizing hormone receptor following substitution of Ser-277 with selective hydrophobic residues in the ectodomain hinge region. J Biol Chem 275:30264–30271.
    OpenUrlAbstract/FREE Full Text
  110. ↵
    1. Nechamen CA,
    2. Thomas RM,
    3. Cohen BD,
    4. Acevedo G,
    5. Poulikakos PI,
    6. Testa JR, and
    7. Dias JA
    (2004) Human follicle-stimulating hormone (FSH) receptor interacts with the adaptor protein APPL1 in HEK 293 cells: potential involvement of the PI3K pathway in FSH signaling. Biol Reprod 71:629–636.
    OpenUrlAbstract/FREE Full Text
  111. ↵
    1. Nechamen CA,
    2. Thomas RM, and
    3. Dias JA
    (2007) APPL1, APPL2, Akt2 and FOXO1a interact with FSHR in a potential signaling complex. Mol Cell Endocrinol 260-262:93–99.
    OpenUrlCrossRefPubMed
  112. ↵
    1. Neubauer K,
    2. Jewgenow K, and
    3. Fickel J
    (2006) Follicle-stimulating hormone receptor in felids: intra- and interspecies variation. Theriogenology 66:1737–1742.
    OpenUrlCrossRefPubMed
  113. ↵
    1. Ng GY,
    2. O’Dowd BF,
    3. Lee SP,
    4. Chung HT,
    5. Brann MR,
    6. Seeman P, and
    7. George SR
    (1996) Dopamine D2 receptor dimers and receptor-blocking peptides. Biochem Biophys Res Commun 227:200–204.
    OpenUrlCrossRefPubMed
  114. ↵
    1. Pierce JG and
    2. Parsons TF
    (1981) Glycoprotein hormones: structure and function. Annu Rev Biochem 50:465–495.
    OpenUrlCrossRefPubMed
  115. ↵
    1. Planeix F,
    2. Siraj MA,
    3. Bidard FC,
    4. Robin B,
    5. Pichon C,
    6. Sastre-Garau X,
    7. Antoine M, and
    8. Ghinea N
    (2015) Endothelial follicle-stimulating hormone receptor expression in invasive breast cancer and vascular remodeling at tumor periphery. J Exp Clin Cancer Res 34:12.
    OpenUrlCrossRefPubMed
  116. ↵
    1. Prior JC
    (2007) FSH and bone—important physiology or not? Trends Mol Med 13:1–3.
    OpenUrlCrossRefPubMed
  117. ↵
    1. Quintana J,
    2. Hipkin RW,
    3. Sánchez-Yagüe J, and
    4. Ascoli M
    (1994) Follitropin (FSH) and a phorbol ester stimulate the phosphorylation of the FSH receptor in intact cells. J Biol Chem 269:8772–8779.
    OpenUrlAbstract/FREE Full Text
  118. ↵
    1. Radu A,
    2. Pichon C,
    3. Camparo P,
    4. Antoine M,
    5. Allory Y,
    6. Couvelard A,
    7. Fromont G,
    8. Hai MT, and
    9. Ghinea N
    (2010) Expression of follicle-stimulating hormone receptor in tumor blood vessels. N Engl J Med 363:1621–1630.
    OpenUrlCrossRefPubMed
  119. ↵
    1. Rajapaksha WR,
    2. Robertson L, and
    3. O’Shaughnessy PJ
    (1996) Expression of follicle-stimulating hormone-receptor mRNA alternate transcripts in bovine granulosa cells during luteinization in vivo and in vitro. Mol Cell Endocrinol 120:25–30.
    OpenUrlCrossRefPubMed
  120. ↵
    1. Reiter E,
    2. Ahn S,
    3. Shukla AK, and
    4. Lefkowitz RJ
    (2012) Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors. Annu Rev Pharmacol Toxicol 52:179–197.
    OpenUrlCrossRefPubMed
  121. ↵
    1. Reiter E and
    2. Lefkowitz RJ
    (2006) GRKs and beta-arrestins: roles in receptor silencing, trafficking and signaling. Trends Endocrinol Metab 17:159–165.
    OpenUrlCrossRefPubMed
  122. ↵
    1. Richards JS,
    2. Russell DL,
    3. Ochsner S,
    4. Hsieh M,
    5. Doyle KH,
    6. Falender AE,
    7. Lo YK, and
    8. Sharma SC
    (2002) Novel signaling pathways that control ovarian follicular development, ovulation, and luteinization. Recent Prog Horm Res 57:195–220.
    OpenUrlCrossRefPubMed
  123. ↵
    1. Rivero-Müller A,
    2. Chou YY,
    3. Ji I,
    4. Lajic S,
    5. Hanyaloglu AC,
    6. Jonas K,
    7. Rahman N,
    8. Ji TH, and
    9. Huhtaniemi I
    (2010) Rescue of defective G protein-coupled receptor function in vivo by intermolecular cooperation. Proc Natl Acad Sci USA 107:2319–2324.
    OpenUrlAbstract/FREE Full Text
  124. ↵
    1. Robinson LJ,
    2. Tourkova I,
    3. Wang Y,
    4. Sharrow AC,
    5. Landau MS,
    6. Yaroslavskiy BB,
    7. Sun L,
    8. Zaidi M, and
    9. Blair HC
    (2010) FSH-receptor isoforms and FSH-dependent gene transcription in human monocytes and osteoclasts. Biochem Biophys Res Commun 394:12–17.
    OpenUrlCrossRefPubMed
  125. ↵
    1. Sairam MR
    (1989) Role of carbohydrates in glycoprotein hormone signal transduction. FASEB J 3:1915–1926.
    OpenUrlAbstract
  126. ↵
    1. Sairam MR and
    2. Bhargavi GN
    (1985) A role for glycosylation of the alpha subunit in transduction of biological signal in glycoprotein hormones. Science 229:65–67.
    OpenUrlAbstract/FREE Full Text
  127. ↵
    1. Sairam MR,
    2. Jiang LG,
    3. Yarney TA, and
    4. Khan H
    (1996) Follitropin signal transduction: alternative splicing of the FSH receptor gene produces a dominant negative form of receptor which inhibits hormone action. Biochem Biophys Res Commun 226:717–722.
    OpenUrlCrossRefPubMed
  128. ↵
    1. Sairam MR,
    2. Jiang LG,
    3. Yarney TA, and
    4. Khan H
    (1997) Alternative splicing converts the G-protein coupled follitropin receptor gene into a growth factor type I receptor: implications for pleiotropic actions of the hormone. Mol Reprod Dev 48:471–479.
    OpenUrlCrossRefPubMed
  129. ↵
    1. Schmidt A,
    2. MacColl R,
    3. Lindau-Shepard B,
    4. Buckler DR, and
    5. Dias JA
    (2001) Hormone-induced conformational change of the purified soluble hormone binding domain of follitropin receptor complexed with single chain follitropin. J Biol Chem 276:23373–23381.
    OpenUrlAbstract/FREE Full Text
  130. ↵
    1. Seibel MJ,
    2. Dunstan CR,
    3. Zhou H,
    4. Allan CM, and
    5. Handelsman DJ
    (2006) Sex steroids, not FSH, influence bone mass. Cell 127: 1079–1071.
    OpenUrlCrossRefPubMed
  131. ↵
    1. Shenoy SK,
    2. Drake MT,
    3. Nelson CD,
    4. Houtz DA,
    5. Xiao K,
    6. Madabushi S,
    7. Reiter E,
    8. Premont RT,
    9. Lichtarge O, and
    10. Lefkowitz RJ
    (2006) beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor. J Biol Chem 281:1261–1273.
    OpenUrlAbstract/FREE Full Text
  132. ↵
    1. Simoni M,
    2. Gromoll J, and
    3. Nieschlag E
    (1997) The follicle-stimulating hormone receptor: biochemistry, molecular biology, physiology, and pathophysiology. Endocr Rev 18:739–773.
    OpenUrlCrossRefPubMed
  133. ↵
    1. Siraj A,
    2. Desestret V,
    3. Antoine M,
    4. Fromont G,
    5. Huerre M,
    6. Sanson M,
    7. Camparo P,
    8. Pichon C,
    9. Planeix F,
    10. Gonin J,
    11. et al.
    (2013) Expression of follicle-stimulating hormone receptor by the vascular endothelium in tumor metastases. BMC Cancer 13:246.
    OpenUrlCrossRefPubMed
  134. ↵
    1. Smits G,
    2. Olatunbosun O,
    3. Delbaere A,
    4. Pierson R,
    5. Vassart G, and
    6. Costagliola S
    (2003) Ovarian hyperstimulation syndrome due to a mutation in the follicle-stimulating hormone receptor. N Engl J Med 349:760–766.
    OpenUrlCrossRefPubMed
  135. ↵
    1. Sohn J,
    2. Ryu K,
    3. Sievert G,
    4. Jeoung M,
    5. Ji I, and
    6. Ji TH
    (2002) Follicle-stimulating hormone interacts with exoloop 3 of the receptor. J Biol Chem 277:50165–50175.
    OpenUrlAbstract/FREE Full Text
  136. ↵
    1. Song GJ,
    2. Park YS,
    3. Lee YS,
    4. Lee CC, and
    5. Kang IS
    (2002) Alternatively spliced variants of the follicle-stimulating hormone receptor gene in the testis of infertile men. Fertil Steril 77:499–504.
    OpenUrlCrossRefPubMed
  137. ↵
    1. Song Y,
    2. Wang ES,
    3. Xing LL,
    4. Shi S,
    5. Qu F,
    6. Zhang D,
    7. Li JY,
    8. Shu J,
    9. Meng Y,
    10. Sheng JZ,
    11. et al.
    (2016) Follicle-stimulating hormone induces postmenopausal dyslipidemia through inhibiting hepatic cholesterol metabolism. J Clin Endocrinol Metab 101:254–263.
    OpenUrlCrossRefPubMed
  138. ↵
    1. Stilley JA,
    2. Christensen DE,
    3. Dahlem KB,
    4. Guan R,
    5. Santillan DA,
    6. England SK,
    7. Al-Hendy A,
    8. Kirby PA, and
    9. Segaloff DL
    (2014a) FSH receptor (FSHR) expression in human extragonadal reproductive tissues and the developing placenta, and the impact of its deletion on pregnancy in mice. Biol Reprod 91:74.
    OpenUrlAbstract/FREE Full Text
  139. ↵
    1. Stilley JA,
    2. Guan R,
    3. Duffy DM, and
    4. Segaloff DL
    (2014b) Signaling through FSH receptors on human umbilical vein endothelial cells promotes angiogenesis. J Clin Endocrinol Metab 99:E813–E820.
    OpenUrlCrossRefPubMed
  140. ↵
    1. Sullivan RR,
    2. Faris BR,
    3. Eborn D,
    4. Grieger DM,
    5. Cino-Ozuna AG, and
    6. Rozell TG
    (2013) Follicular expression of follicle stimulating hormone receptor variants in the ewe. Reprod Biol Endocrinol 11:113.
    OpenUrlCrossRefPubMed
  141. ↵
    1. Sun L,
    2. Peng Y,
    3. Sharrow AC,
    4. Iqbal J,
    5. Zhang Z,
    6. Papachristou DJ,
    7. Zaidi S,
    8. Zhu LL,
    9. Yaroslavskiy BB,
    10. Zhou H,
    11. et al.
    (2006) FSH directly regulates bone mass. Cell 125:247–260.
    OpenUrlCrossRefPubMed
  142. ↵
    1. Sun L,
    2. Zhang Z,
    3. Zhu LL,
    4. Peng Y,
    5. Liu X,
    6. Li J,
    7. Agrawal M,
    8. Robinson LJ,
    9. Iqbal J,
    10. Blair HC,
    11. et al.
    (2010) Further evidence for direct pro-resorptive actions of FSH. Biochem Biophys Res Commun 394:6–11.
    OpenUrlCrossRefPubMed
  143. ↵
    1. Szkudlinski MW
    (2015) New frontier in glycoprotein hormones and their receptors structure-function. Front Endocrinol (Lausanne) 6:155.
    OpenUrlPubMed
  144. ↵
    1. Tao YX,
    2. Johnson NB, and
    3. Segaloff DL
    (2004) Constitutive and agonist-dependent self-association of the cell surface human lutropin receptor. J Biol Chem 279:5904–5914.
    OpenUrlAbstract/FREE Full Text
  145. ↵
    1. Tena-Sempere M,
    2. Manna PR, and
    3. Huhtaniemi I
    (1999) Molecular cloning of the mouse follicle-stimulating hormone receptor complementary deoxyribonucleic acid: functional expression of alternatively spliced variants and receptor inactivation by a C566T transition in exon 7 of the coding sequence. Biol Reprod 60:1515–1527.
    OpenUrlAbstract/FREE Full Text
  146. ↵
    1. Thomas RM,
    2. Nechamen CA,
    3. Mazurkiewicz JE,
    4. Muda M,
    5. Palmer S, and
    6. Dias JA
    (2007) Follice-stimulating hormone receptor forms oligomers and shows evidence of carboxyl-terminal proteolytic processing. Endocrinology 148:1987–1995.
    OpenUrlCrossRefPubMed
  147. ↵
    1. Thomas RM,
    2. Nechamen CA,
    3. Mazurkiewicz JE,
    4. Ulloa-Aguirre A, and
    5. Dias JA
    (2011) The adapter protein APPL1 links FSH receptor to inositol 1,4,5-trisphosphate production and is implicated in intracellular Ca(2+) mobilization. Endocrinology 152:1691–1701.
    OpenUrlCrossRefPubMed
  148. ↵
    1. Timossi C,
    2. Damián-Matsumura P,
    3. Dominguez-González A, and
    4. Ulloa-Aguirre A
    (1998) A less acidic human follicle-stimulating hormone preparation induces tissue-type plasminogen activator enzyme activity earlier than a predominantly acidic analogue in phenobarbital-blocked pro-oestrous rats. Mol Hum Reprod 4:1032–1038.
    OpenUrlAbstract/FREE Full Text
  149. ↵
    1. Timossi CM,
    2. Barrios-de-Tomasi J,
    3. González-Suárez R,
    4. Arranz MC,
    5. Padmanabhan V,
    6. Conn PM, and
    7. Ulloa-Aguirre A
    (2000) Differential effects of the charge variants of human follicle-stimulating hormone. J Endocrinol 165:193–205.
    OpenUrlAbstract
  150. ↵
    1. Touraine P,
    2. Beau I,
    3. Gougeon A,
    4. Meduri G,
    5. Desroches A,
    6. Pichard C,
    7. Detoeuf M,
    8. Paniel B,
    9. Prieur M,
    10. Zorn JR,
    11. et al.
    (1999) New natural inactivating mutations of the follicle-stimulating hormone receptor: correlations between receptor function and phenotype. Mol Endocrinol 13:1844–1854.
    OpenUrlCrossRefPubMed
  151. ↵
    1. Tranchant T,
    2. Durand G,
    3. Gauthier C,
    4. Crépieux P,
    5. Ulloa-Aguirre A,
    6. Royère D, and
    7. Reiter E
    (2011) Preferential β-arrestin signalling at low receptor density revealed by functional characterization of the human FSH receptor A189 V mutation. Mol Cell Endocrinol 331:109–118.
    OpenUrlCrossRefPubMed
  152. ↵
    1. Troispoux C,
    2. Guillou F,
    3. Elalouf JM,
    4. Firsov D,
    5. Iacovelli L,
    6. De Blasi A,
    7. Combarnous Y, and
    8. Reiter E
    (1999) Involvement of G protein-coupled receptor kinases and arrestins in desensitization to follicle-stimulating hormone action. Mol Endocrinol 13:1599–1614.
    OpenUrlCrossRefPubMed
  153. ↵
    1. Troppmann B,
    2. Kleinau G,
    3. Krause G, and
    4. Gromoll J
    (2013) Structural and functional plasticity of the luteinizing hormone/choriogonadotrophin receptor. Hum Reprod Update 19:583–602.
    OpenUrlAbstract/FREE Full Text
  154. ↵
    1. Uchida S,
    2. Uchida H,
    3. Maruyama T,
    4. Kajitani T,
    5. Oda H,
    6. Miyazaki K,
    7. Kagami M, and
    8. Yoshimura Y
    (2013) Molecular analysis of a mutated FSH receptor detected in a patient with spontaneous ovarian hyperstimulation syndrome. PLoS One 8:e75478.
    OpenUrlCrossRefPubMed
  155. ↵
    1. Ulloa-Aguirre A,
    2. Janovick JA,
    3. Brothers SP, and
    4. Conn PM
    (2004) Pharmacologic rescue of conformationally-defective proteins: implications for the treatment of human disease. Traffic 5:821–837.
    OpenUrlCrossRefPubMed
  156. ↵
    1. Ulloa-Aguirre A,
    2. Midgley AR Jr.,
    3. Beitins IZ, and
    4. Padmanabhan V
    (1995) Follicle-stimulating isohormones: characterization and physiological relevance. Endocr Rev 16:765–787.
    OpenUrlCrossRefPubMed
  157. ↵
    1. Ulloa-Aguirre A,
    2. Reiter E,
    3. Bousfield G,
    4. Dias JA, and
    5. Huhtaniemi I
    (2014a) Constitutive activity in gonadotropin receptors. Adv Pharmacol 70:37–80.
    OpenUrlCrossRefPubMed
  158. ↵
    1. Ulloa-Aguirre A and
    2. Timossi C
    (1998) Structure-function relationship of follicle-stimulating hormone and its receptor. Hum Reprod Update 4:260–283.
    OpenUrlAbstract/FREE Full Text
  159. ↵
    1. Ulloa-Aguirre A,
    2. Timossi C,
    3. Barrios-de-Tomasi J,
    4. Maldonado A, and
    5. Nayudu P
    (2003) Impact of carbohydrate heterogeneity in function of follicle-stimulating hormone: studies derived from in vitro and in vivo models. Biol Reprod 69:379–389.
    OpenUrlAbstract/FREE Full Text
  160. ↵
    1. Ulloa-Aguirre A,
    2. Uribe A,
    3. Zariñán T,
    4. Bustos-Jaimes I,
    5. Pérez-Solis MA, and
    6. Dias JA
    (2007a) Role of the intracellular domains of the human FSH receptor in G(alphaS) protein coupling and receptor expression. Mol Cell Endocrinol 260-262:153–162.
    OpenUrl
  161. ↵
    1. Ulloa-Aguirre A,
    2. Zariñán T,
    3. Dias JA, and
    4. Conn PM
    (2014b) Mutations in G protein-coupled receptors that impact receptor trafficking and reproductive function. Mol Cell Endocrinol 382:411–423.
    OpenUrlCrossRefPubMed
  162. ↵
    1. Ulloa-Aguirre A,
    2. Zariñán T,
    3. Pasapera AM,
    4. Casas-González P, and
    5. Dias JA
    (2007b) Multiple facets of follicle-stimulating hormone receptor function. Endocrine 32:251–263.
    OpenUrlCrossRefPubMed
  163. ↵
    1. Uribe A,
    2. Zariñán T,
    3. Pérez-Solis MA,
    4. Gutiérrez-Sagal R,
    5. Jardón-Valadez E,
    6. Piñeiro A,
    7. Dias JA, and
    8. Ulloa-Aguirre A
    (2008) Functional and structural roles of conserved cysteine residues in the carboxyl-terminal domain of the follicle-stimulating hormone receptor in human embryonic kidney 293 cells. Biol Reprod 78:869–882.
    OpenUrlAbstract/FREE Full Text
  164. ↵
    1. Urizar E,
    2. Montanelli L,
    3. Loy T,
    4. Bonomi M,
    5. Swillens S,
    6. Gales C,
    7. Bouvier M,
    8. Smits G,
    9. Vassart G, and
    10. Costagliola S
    (2005) Glycoprotein hormone receptors: link between receptor homodimerization and negative cooperativity. EMBO J 24:1954–1964.
    OpenUrlAbstract/FREE Full Text
  165. ↵
    1. Vassart G and
    2. Costagliola S
    (2011) G protein-coupled receptors: mutations and endocrine diseases. Nat Rev Endocrinol 7:362–372.
    OpenUrlCrossRefPubMed
  166. ↵
    1. Vassart G,
    2. Pardo L, and
    3. Costagliola S
    (2004) A molecular dissection of the glycoprotein hormone receptors. Trends Biochem Sci 29:119–126.
    OpenUrlCrossRefPubMed
  167. ↵
    1. Vasseur C,
    2. Rodien P,
    3. Beau I,
    4. Desroches A,
    5. Gérard C,
    6. de Poncheville L,
    7. Chaplot S,
    8. Savagner F,
    9. Croué A,
    10. Mathieu E,
    11. et al.
    (2003) A chorionic gonadotropin-sensitive mutation in the follicle-stimulating hormone receptor as a cause of familial gestational spontaneous ovarian hyperstimulation syndrome. N Engl J Med 349:753–759.
    OpenUrlCrossRefPubMed
  168. ↵
    1. Venkatakrishnan AJ,
    2. Deupi X,
    3. Lebon G,
    4. Tate CG,
    5. Schertler GF, and
    6. Babu MM
    (2013) Molecular signatures of G-protein-coupled receptors. Nature 494:185–194.
    OpenUrlCrossRefPubMed
  169. ↵
    1. Vlaeminck-Guillem V,
    2. Ho SC,
    3. Rodien P,
    4. Vassart G, and
    5. Costagliola S
    (2002) Activation of the cAMP pathway by the TSH receptor involves switching of the ectodomain from a tethered inverse agonist to an agonist. Mol Endocrinol 16:736–746.
    OpenUrlCrossRefPubMed
  170. ↵
    1. Wallrabe H,
    2. Bonamy G,
    3. Periasamy A, and
    4. Barroso M
    (2007) Receptor complexes cotransported via polarized endocytic pathways form clusters with distinct organizations. Mol Biol Cell 18:2226–2243.
    OpenUrlAbstract/FREE Full Text
  171. ↵
    1. Walton WJ,
    2. Nguyen VT,
    3. Butnev VY,
    4. Singh V,
    5. Moore WT, and
    6. Bousfield GR
    (2001) Characterization of human FSH isoforms reveals a nonglycosylated beta-subunit in addition to the conventional glycosylated beta-subunit. J Clin Endocrinol Metab 86:3675–3685.
    OpenUrlCrossRefPubMed
  172. ↵
    1. Wayne CM,
    2. Fan HY,
    3. Cheng X, and
    4. Richards JS
    (2007) Follicle-stimulating hormone induces multiple signaling cascades: evidence that activation of Rous sarcoma oncogene, RAS, and the epidermal growth factor receptor are critical for granulosa cell differentiation. Mol Endocrinol 21:1940–1957.
    OpenUrlCrossRefPubMed
  173. ↵
    1. Wehbi V,
    2. Tranchant T,
    3. Durand G,
    4. Musnier A,
    5. Decourtye J,
    6. Piketty V,
    7. Butnev VY,
    8. Bousfield GR,
    9. Crépieux P,
    10. Maurel MC,
    11. et al.
    (2010) Partially deglycosylated equine LH preferentially activates beta-arrestin-dependent signaling at the follicle-stimulating hormone receptor. Mol Endocrinol 24:561–573.
    OpenUrlCrossRefPubMed
  174. ↵
    1. Wei H,
    2. Ahn S,
    3. Shenoy SK,
    4. Karnik SS,
    5. Hunyady L,
    6. Luttrell LM, and
    7. Lefkowitz RJ
    (2003) Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci USA 100:10782–10787.
    OpenUrlAbstract/FREE Full Text
  175. ↵
    1. Williams GR
    (2007) Hypogonadal bone loss: sex steroids or gonadotropins? Endocrinology 148:2610–2612.
    OpenUrlCrossRefPubMed
  176. ↵
    1. Yamashita S,
    2. Nakamura K,
    3. Omori Y,
    4. Tsunekawa K,
    5. Murakami M, and
    6. Minegishi T
    (2005) Association of human follitropin (FSH) receptor with splicing variant of human lutropin/choriogonadotropin receptor negatively controls the expression of human FSH receptor. Mol Endocrinol 19:2099–2111.
    OpenUrlCrossRefPubMed
  177. ↵
    1. Yarney TA,
    2. Fahmy MH,
    3. Sairam MR,
    4. Khan H, and
    5. Macdonald EA
    (1997a) Ontogeny of FSH receptor messenger ribonucleic acid transcripts in relation to FSH secretion and testicular function in sheep. J Mol Endocrinol 18:113–125.
    OpenUrlAbstract/FREE Full Text
  178. ↵
    1. Yarney TA,
    2. Jiang L,
    3. Khan H,
    4. MacDonald EA,
    5. Laird DW, and
    6. Sairam MR
    (1997b) Molecular cloning, structure, and expression of a testicular follitropin receptor with selective alteration in the carboxy terminus that affects signaling function. Mol Reprod Dev 48:458–470.
    OpenUrlCrossRefPubMed
  179. ↵
    1. Zariñán T,
    2. Perez-Solís MA,
    3. Maya-Núñez G,
    4. Casas-González P,
    5. Conn PM,
    6. Dias JA, and
    7. Ulloa-Aguirre A
    (2010) Dominant negative effects of human follicle-stimulating hormone receptor expression-deficient mutants on wild-type receptor cell surface expression. Rescue of oligomerization-dependent defective receptor expression by using cognate decoys. Mol Cell Endocrinol 321:112–122.
    OpenUrlCrossRefPubMed
  180. ↵
    1. Zeleznik AJ,
    2. Saxena D, and
    3. Little-Ihrig L
    (2003) Protein kinase B is obligatory for follicle-stimulating hormone-induced granulosa cell differentiation. Endocrinology 144:3985–3994.
    OpenUrlCrossRefPubMed
  181. ↵
    1. Zhang M,
    2. Tao YX,
    3. Ryan GL,
    4. Feng X,
    5. Fanelli F, and
    6. Segaloff DL
    (2007) Intrinsic differences in the response of the human lutropin receptor versus the human follitropin receptor to activating mutations. J Biol Chem 282:25527–25539.
    OpenUrlAbstract/FREE Full Text
  182. ↵
    1. Zhang M,
    2. Tong KP,
    3. Fremont V,
    4. Chen J,
    5. Narayan P,
    6. Puett D,
    7. Weintraub BD, and
    8. Szkudlinski MW
    (2000) The extracellular domain suppresses constitutive activity of the transmembrane domain of the human TSH receptor: implications for hormone-receptor interaction and antagonist design. Endocrinology 141:3514–3517.
    OpenUrlCrossRefPubMed
  183. ↵
    1. Zhou J,
    2. Huang Y,
    3. Li L,
    4. Zhu L,
    5. Zhang D,
    6. Zhang S, and
    7. Chen Y
    (2013) Identification of two novel, alternatively spliced mRNA transcripts of the human follicle-stimulating hormone receptor. Mol Reprod Dev 80:916–923.
    OpenUrlCrossRefPubMed
  184. ↵
    1. Zhu X and
    2. Wess J
    (1998) Truncated V2 vasopressin receptors as negative regulators of wild-type V2 receptor function. Biochemistry 37:15773–15784.
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 90 (5)
Molecular Pharmacology
Vol. 90, Issue 5
1 Nov 2016
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The Follitropin Receptor: Matching Structure and Function
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleMinireview—A Latin American Perspective On G Protein-Coupled Receptors

Follitropin Receptor Structure and Function

Alfredo Ulloa-Aguirre and Teresa Zariñán
Molecular Pharmacology November 1, 2016, 90 (5) 596-608; DOI: https://doi.org/10.1124/mol.116.104398

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleMinireview—A Latin American Perspective On G Protein-Coupled Receptors

Follitropin Receptor Structure and Function

Alfredo Ulloa-Aguirre and Teresa Zariñán
Molecular Pharmacology November 1, 2016, 90 (5) 596-608; DOI: https://doi.org/10.1124/mol.116.104398
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Visual Overview
    • Abstract
    • Introduction
    • FSHR Structure
    • Extragonadal Expression of the FSHR
    • Ligand Binding and Receptor Activation: Role of the FSHR Ectodomain
    • FSHR Self-Association
    • Signal Transduction at the FSHR: Multiple Interacting Partners, Signaling Networks, and Functional Selectivity
    • Concluding Remarks
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Histamine H3 Receptor
  • GPCR-Biased Signaling
  • Gβγ Pathways in Oncogenic GPCR Signaling
Show more Minireview—A Latin American Perspective On G Protein-Coupled Receptors

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics